[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 632
1. Raasch B, Woolley T: Management of primary superficial basal cell carcinoma. Aust Fam Physician; 2006 Jun;35(6):455-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary superficial basal cell carcinoma.
  • BACKGROUND: Superficial basal cell carcinoma (SBCC) is a skin cancer commonly treated by general practitioners.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Subcutaneous Tissue

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16751865.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  •  go-up   go-down


2. Patel R, Adsay V, Andea A: Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma. Rare Tumors; 2010;2(1):e8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with progression to metastatic neuroendocrine carcinoma.
  • Merkel cell carcinoma (MCC) or primary cutaneous neuroendocrine carcinoma is a malignant tumor considered to demonstrate differentiation towards Merkel cells that are present at the base of the epidermis or around the apical end of some hair follicles and are thought to play a yet uncertain role in sensory transduction.
  • Here we present the case of a 54- year old female with a basal cell carcinoma (BCC) of the skin with neuroendocrine features (positivity for chromogranin) that has evolved during multiple recurrences and radiotherapy into a high-grade neuroendocrine carcinoma with morphological and immunohistochemical features of MCC (trabecular and nesting arrangement, positivity for chromogranin, cytokeratin 20, neuron specific enolase, and also neurosecretory granules on electron microscopy).
  • The progression from a chromogranin positive basal cell carcinoma of the skin, to a high-grade neuroendocrine carcinoma demonstrates the potential for cross differentiation among skin tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139953.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994488
  • [Keywords] NOTNLM ; Merkel cell carcinoma / basal cell carcinoma / neuroendocrine
  •  go-up   go-down


3. Bostock-Ling N: Excising basal cell carcinoma in general practice. Aust Fam Physician; 2006 Jul;35(7):558-60
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excising basal cell carcinoma in general practice.
  • BACKGROUND: Currently there is much interest in the general practice management of basal cell carcinoma (BCC).
  • RESULTS: Thirty-nine percent of BCCs in this series were located on the head or neck, compared with 75-94% from other series; 50% of BCCs from the head/neck contained an aggressive histological subtype, compared with only 10% from other sites; four out of 139 papers found regarding surgical management of BCCs were from primary care practice.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Family Practice / statistics & numerical data. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16820836.001).
  • [ISSN] 0300-8495
  • [Journal-full-title] Australian family physician
  • [ISO-abbreviation] Aust Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


Advertisement
4. Akinyemi E, Mai L, Matin A, Maini A: Diffuse large B-cell lymphoma mimicking advanced basal cell carcinoma. J Natl Med Assoc; 2007 Aug;99(8):948-50
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma mimicking advanced basal cell carcinoma.
  • Primary cutaneous B-cell lymphomas (PCBCLs) are made up of a heterogenous group of B-cell lymphoproliferative diseases confined to the skin at the time of diagnosis with no evidence of extracutaneous involvement.
  • With early diagnosis and adequate treatment, PCBCLs as a group has excellent prognosis, with about a 95% survival rate at five years.
  • We report a case of diffuse large B-cell lymphoma (DLBCL) in a 52-year-old woman presenting as a fungating skin ulcer mimicking advanced basal cell carcinoma.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Basal Cell. Combined Modality Therapy. Cyclophosphamide. Doxorubicin. Female. Humans. Middle Aged. Prednisolone. Rituximab. Treatment Outcome. Vincristine

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathology. 2002 Feb;34(1):36-45 [11902444.001]
  • [Cites] Br J Dermatol. 2002 Jan;146(1):144-7 [11841383.001]
  • [Cites] Australas J Dermatol. 2003 May;44(2):110-5 [12752183.001]
  • [Cites] Br J Dermatol. 2003 Dec;149(6):1183-91 [14674895.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):385-9 [8407414.001]
  • [Cites] J Am Acad Dermatol. 1994 Jul;31(1):54-60 [8021372.001]
  • [Cites] Blood. 1997 Jul 1;90(1):354-71 [9207472.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2080-5 [9626207.001]
  • [Cites] Am J Dermatopathol. 1999 Jun;21(3):265-73 [10380050.001]
  • [Cites] Br J Dermatol. 2005 Mar;152(3):541-4 [15787825.001]
  • [Cites] Radiother Oncol. 1999 Jul;52(1):15-8 [10577681.001]
  • [Cites] Blood. 2000 May 15;95(10):3052-6 [10807768.001]
  • [Cites] Br J Dermatol. 2000 May;142(5):913-23 [10809848.001]
  • [Cites] Cancer. 2000 Oct 15;89(8):1835-44 [11042581.001]
  • [Cites] Pathol Int. 2000 Dec;50(12):960-6 [11123762.001]
  • [Cites] Br J Dermatol. 2001 Jun;144(6):1239-43 [11422050.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):647-55 [11821444.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):574-80 [11939732.001]
  • (PMID = 17722675.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Other-IDs] NLM/ PMC2574298
  •  go-up   go-down


5. Østergaard J, Boberg-Ans J, Prause JU, Heegaard S: Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva. Graefes Arch Clin Exp Ophthalmol; 2005 Jun;243(6):615-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basal cell carcinoma of the caruncle with seeding to the conjunctiva.
  • BACKGROUND: To report the clinical and histopathological characteristics of a patient with a primary basal cell carcinoma (BCC) of the caruncle with seeding of the tumour to the conjunctiva.
  • Microscopically, both neoplasms were composed of infiltrative islands of basaloid tumour cells, scattered mitoses and peripheral palisading consistent with the diagnosis of BCC.
  • CONCLUSION: This case describes a primary BCC of the caruncle with seeding to the conjunctiva.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Conjunctival Neoplasms / secondary. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / diagnosis
  • [MeSH-minor] Diagnosis, Differential. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Metastasis. Ophthalmologic Surgical Procedures / methods. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Tears.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15614536.001).
  • [ISSN] 1435-702X
  • [Journal-full-title] Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv für klinische und experimentelle Ophthalmologie
  • [ISO-abbreviation] Graefes Arch. Clin. Exp. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Mosterd K, Arits AH, Thissen MR, Kelleners-Smeets NW: Histology-based treatment of basal cell carcinoma. Acta Derm Venereol; 2009;89(5):454-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histology-based treatment of basal cell carcinoma.
  • Basal cell carcinoma is the most common type of skin cancer and its incidence is still rising.
  • Selection criteria were histological subtype, primary or recurrent basal cell carcinoma and tumour localization.
  • Although surgery remains the preferred treatment for most basal cell carcinomas, patient and tumour characteristics should be taken into account when choosing the most suitable treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Cryotherapy. Mohs Surgery. Photochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Evidence-Based Medicine. Humans. Neoplasm Invasiveness. Patient Selection. Randomized Controlled Trials as Topic. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Derm Venereol. 2009;89(5):450-2 [19734965.001]
  • [ErratumIn] Acta Derm Venereol. 2009 Nov;89(6):667
  • (PMID = 19734968.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 36
  •  go-up   go-down


7. Boswell JS, Flam MS, Tashjian DN, Tschang TP: Basal cell carcinoma metastatic to cervical lymph nodes and lungs. Dermatol Online J; 2006;12(6):9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma metastatic to cervical lymph nodes and lungs.
  • Metastatic basal cell carcinoma (MBCC) of the skin is rare in occurrence and may initially elude proper diagnosis and management.
  • We describe a case of MBCC to cervical lymph nodes, originally evaluated and treated surgically as metastatic thyroid carcinoma.
  • After definitive diagnosis of MBCC was made, chemotherapy and concomitant radiation treatment were initiated; however, despite these measures, the patient then developed MBCC to the lung.
  • In addition to the more commonly metastasizing carcinomas, metastases from a cutaneous basal cell carcinoma primary tumor should be considered when evaluating cervical lymph node metastases of an uncertain head and neck primary.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Carcinoma, Papillary / diagnosis. Diagnostic Errors. Head and Neck Neoplasms / diagnosis. Lung Neoplasms / secondary. Lymphatic Metastasis. Thyroid Neoplasms / diagnosis
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy, Fine-Needle. Carboplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Male. Middle Aged. Neck Dissection. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Second Primary. Radiotherapy. Seminoma. Skin Neoplasms / surgery. Taxoids / administration & dosage. Testicular Neoplasms. Thyroidectomy. Unnecessary Procedures

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083889.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


8. Hamada S, Kersey T, Thaller VT: Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome. Br J Ophthalmol; 2005 Aug;89(8):992-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid basal cell carcinoma: non-Mohs excision, repair, and outcome.
  • AIM: To analyse the outcome of basal cell carcinoma (BCC) excision in a subregional (non-Mohs) oculoplastic service.
  • The pathology revealed 84% complete primary excision.
  • 70% of lid defects were treated by primary direct closure.
  • The overall 5 year and over recurrence rate including previously recurrent BCCs was 4.35%, only one of which was in the primary BCC group (1.6%).
  • [MeSH-major] Blepharoplasty / methods. Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 1967 Jun;39(6):619-24 [6026420.001]
  • [Cites] N Engl J Med. 1965 Oct 21;273(17):923-4 [5832875.001]
  • [Cites] J Surg Oncol. 1984 Feb;25(2):79-80 [6694405.001]
  • [Cites] J Surg Oncol. 1985 Jan;28(1):72-4 [3968892.001]
  • [Cites] J Am Acad Dermatol. 1986 Feb;14(2 Pt 1):186-96 [3950119.001]
  • [Cites] Mod Pathol. 1991 May;4(3):325-30 [2068058.001]
  • [Cites] Ophthalmic Surg. 1993 Nov;24(11):755-8 [8290215.001]
  • [Cites] Clin Plast Surg. 1997 Oct;24(4):673-86 [9342510.001]
  • [Cites] Plast Reconstr Surg. 1982 Jan;69(1):110-6 [7053498.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):631-6 [15051193.001]
  • [Cites] AORN J. 2000 Mar;71(3):552-4, 556-8, 560-4; quiz 565-70 [10736640.001]
  • [Cites] Acta Ophthalmol Scand. 2000 Aug;78(4):430-6 [10990046.001]
  • [Cites] Br J Ophthalmol. 2001 Dec;85(12):1450-4 [11734520.001]
  • [Cites] Dermatol Surg. 2004 Feb;30(2 Pt 2):257-63 [14871219.001]
  • [Cites] Br J Ophthalmol. 2004 Mar;88(3):358-60 [14977769.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):624-30 [15051192.001]
  • [CommentIn] Br J Ophthalmol. 2006 Jul;90(7):926; author reply 926-7 [16782962.001]
  • [CommentIn] Br J Ophthalmol. 2006 May;90(5):660-1 [16622110.001]
  • (PMID = 16024851.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1772767
  •  go-up   go-down


9. Mencía-Gutiérrez E, Gutiérrez-Díaz E, Pérez-Martín ME: Lacrimal caruncle primary basal cell carcinoma: case report and review. J Cutan Pathol; 2005 Aug;32(7):502-5
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lacrimal caruncle primary basal cell carcinoma: case report and review.
  • BACKGROUND: Basal cell carcinoma (BCC) is a common malignant skin neoplasm.
  • Consequently, the caruncle may spawn any neoplasm that occurs in the conjunctiva, skin, or lacrimal gland.
  • We report a patient with a primary BCC located on the lacrimal caruncle.
  • METHODS: An 80-year-old man with a 5-month history of a gradually enlarging left caruncular neoplasm was seen.
  • He had a history of sun exposure, but no personal or family history of other malignant neoplasms.
  • Histopathologic examination revealed a BCC originating in the basal layer of the conjunctival epithelium.
  • Primary BCC of the caruncle is unusual, and only four cases have been described in the PubMed.
  • BCC should be considered in the differential diagnosis of caruncle and adjacent skin lesions.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Eye Neoplasms / pathology. Lacrimal Apparatus / pathology. Lacrimal Apparatus Diseases / pathology

  • MedlinePlus Health Information. consumer health - Eye Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16008695.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 9
  •  go-up   go-down


10. Essers BA, van Helvoort-Postulart D, Prins MH, Neumann M, Dirksen CD: Does the inclusion of a cost attribute result in different preferences for the surgical treatment of primary basal cell carcinoma?: a comparison of two discrete-choice experiments. Pharmacoeconomics; 2010;28(6):507-20
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the inclusion of a cost attribute result in different preferences for the surgical treatment of primary basal cell carcinoma?: a comparison of two discrete-choice experiments.
  • OBJECTIVE: To examine whether the inclusion of a cost attribute in a DCE results in different preferences regarding a surgical treatment for primary basal cell carcinoma (BCC) compared with a DCE without a cost attribute.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Carcinoma, Basal Cell / surgery. Choice Behavior. Cost-Benefit Analysis / methods. Health Care Costs. Patient Preference / economics. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20387912.001).
  • [ISSN] 1179-2027
  • [Journal-full-title] PharmacoEconomics
  • [ISO-abbreviation] Pharmacoeconomics
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] New Zealand
  •  go-up   go-down


11. Rodriguez-Vigil T, Vázquez-López F, Perez-Oliva N: Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation. J Am Acad Dermatol; 2007 Jan;56(1):91-5
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence rates of primary basal cell carcinoma in facial risk areas treated with curettage and electrodesiccation.
  • BACKGROUND: The incidence of basal cell carcinoma (BCC) is increasing.
  • OBJECTIVE: We sought to evaluate the cumulative recurrence rate (RR) of primary BCC in facial areas of medium and high risk after CE.
  • METHODS: This nonrandomized, clinical trial enrolled 257 patients with primary BCC located in medium- and high-risk facial areas, and treated with 4 or 5 cycles of CE by a single operator from a section specializing in BCC CE in a tertiary teaching hospital in Oviedo, Spain.
  • The primary outcome was recurrence of carcinoma, which was clinically evaluated by at least two observers in consensus.
  • CONCLUSION: High 5-year cure rates can be obtained after CE of primary, nonfibrosing BCCs of medium- and high-risk areas of the face performed in a specialized section.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Curettage. Electrocoagulation. Facial Neoplasms / epidemiology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17190625.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Komorski JA, Nienartowicz JM: [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis]. Otolaryngol Pol; 2009 Sep-Oct;63(5):442-7
Genetic Alliance. consumer health - Acinic Cell Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acinic cell carcinoma of glandule parotidea presenting untypical clinical symptoms and their bad prognosis].
  • [Transliterated title] Acinic cell carcinoma ślinianki przyusznej o nietypowym obrazie klinicznym i niekorzystnym przebiegu.
  • Differential diagnosis of neck tumours puts precedence on diagnosing neoplastic lesions.
  • In the case of neck tumours, these are unfortunately late signs, but in patients with a primary neoplastic focus within the head and neck, neck tumour is often the first sign of the disease.
  • The preoperative histopathological diagnosis using thin-needle biopsy: cellulae carcinomatosae and the clinical picture resulted in block operation with neck lymphatic system removal and tissue defect reconstruction by means of a pectoral flap.
  • The histopathological examination confirmed non-cornifying basal cell epithelioma only in the essential lesion with no metastases to lymph nodes and surrounding tissue margins free of infiltrates.
  • In the collected specimen of the tumour on the front thoracic wall, a diagnosis of acinic cell carcinoma was made.
  • [MeSH-major] Carcinoma, Acinar Cell / pathology. Carcinoma, Acinar Cell / surgery. Parotid Neoplasms / pathology. Parotid Neoplasms / surgery
  • [MeSH-minor] Aged. Head and Neck Neoplasms / secondary. Humans. Male. Neck Dissection / methods. Neoplasm Staging. Palliative Care. Prognosis. Thoracic Wall / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169911.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


13. Córdoba S, Hernández A, Romero A, Arias D, Castaño E, García-Donoso C, Borbujo JM: [Basal cell carcinoma overlying a dermatofibroma]. Actas Dermosifiliogr; 2005 Nov;96(9):612-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Basal cell carcinoma overlying a dermatofibroma].
  • [Transliterated title] Carcinoma basocelular sobre dermatofibroma.
  • The epidermis over a dermatofibroma may show changes that range from simple hyperplasia to the proliferation of basaloid cells, which can become morphologically indistinguishable from basal cell carcinoma.
  • The existence of a true basal cell carcinoma overlying a dermatofibroma is infrequent.
  • We describe a case of dermatofibroma that presented with a basaloid proliferation identical in appearance to a basal cell carcinoma on the overlying epidermis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Histiocytoma, Benign Fibrous / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Dermatofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16476308.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Essers BA, Dirksen CD, Prins MH, Neumann HA: Assessing the public's preference for surgical treatment of primary basal cell carcinoma: a discrete-choice experiment in the south of the Netherlands. Dermatol Surg; 2010 Dec;36(12):1950-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the public's preference for surgical treatment of primary basal cell carcinoma: a discrete-choice experiment in the south of the Netherlands.
  • BACKGROUND: Basal cell carcinoma (BCC) is a slowly growing nonmelanoma type of skin cancer that often is located on the face.
  • METHODS: A discrete-choice experiment (DCE) was conducted among members of the general public to examine which attributes of a surgical treatment for primary BCC are valued as important.
  • CONCLUSIONS: Results from this DCE indicate that, when outcome and process attributes are considered from a societal perspective, MMS is preferred over SE for primary BCC.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Mohs Surgery. Public Opinion. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / psychology. Netherlands. Reoperation / psychology. Risk. Surveys and Questionnaires. Time Factors. Travel. Waiting Lists

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 by the American Society for Dermatologic Surgery, Inc.
  • (PMID = 21070461.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Bath-Hextall FJ, Perkins W, Bong J, Williams HC: Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev; 2007;(1):CD003412
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interventions for basal cell carcinoma of the skin.
  • BACKGROUND: Basal cell carcinoma (BCC) is the commonest skin cancer.
  • OBJECTIVES: To assess the effects of treatments for basal cell carcinoma.
  • SELECTION CRITERIA: Inclusion criteria were adults with one or more histologically proven, primary basal cell carcinoma.
  • The primary outcome measure was recurrence at three to five years, measured clinically.
  • Only one RCT of surgery versus radiotherapy had primary outcome data at four years, showing significantly more persistent tumours and recurrences in the radiotherapy group as compared to the surgery group, (RR 0.09, 95%CI, 0.01 to 0.69).
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateOf] Cochrane Database Syst Rev. 2003;(2):CD003412 [12804465.001]
  • (PMID = 17253489.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 63
  •  go-up   go-down


16. Dogan G: Basal cell carcinoma in outdoor versus indoor workers in Turkey. Int J Dermatol; 2007 Jan;46(1):43-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in outdoor versus indoor workers in Turkey.
  • BACKGROUND: Basal cell carcinoma remains a significant health problem, and is most common in people of Caucasian origin with significant sun exposure.
  • This study investigated differences between two groups of Turkish patients with basal cell carcinoma: indoor workers versus outdoor workers.
  • METHODS: One hundred and twenty-one patients with primary basal cell carcinoma were categorized as outdoor (Group OW) or indoor workers (Group IW), according to sun exposure at work.
  • CONCLUSIONS: The results in the Turkish population of the study suggest that basal cell carcinoma may develop in indoor workers (intermittent sun exposure) earlier than in outdoor workers with chronic sun-exposure, but more aggressive subtypes are more likely to be linked with chronic sun-exposure.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Skin Neoplasms / epidemiology. Workplace

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214718.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Blázquez-Sánchez N, de Troya-Martín M, Frieyro-Elicegui M, Fúnez-Liébana R, Martín-Márquez L, Rivas-Ruiz F: Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma. Actas Dermosifiliogr; 2010 Sep;101(7):622-628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost Analysis of Mohs Micrographic Surgery in High-Risk Facial Basal Cell Carcinoma.
  • [Transliterated title] Análisis de costes de la cirugía micrográfica de Mohs en el carcinoma basocelular facial de alto riesgo.
  • INTRODUCTION: Mohs micrographic surgery (MMS) is the treatment of choice for high-risk facial basal cell carcinoma (BCC) as it offers the greatest chance of cure with maximum preservation of healthy tissue.
  • RESULTS: Seventy-nine patients (mean age, 62 years) with 81 high-risk facial BCCs, 97.5% of which were primary tumors, underwent MMS.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier España, S.L. y AEDV. All rights reserved.
  • (PMID = 28709544.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliograficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Keywords] NOTNLM ; Análisis de costes / Cirugía micrográfica / Cost analysis / Cost-effectiveness / Coste/beneficio / Micrographic surgery / Mohs
  •  go-up   go-down


18. Rustemeyer J, Thieme V, Günther L, Bremerich A: [Experiences with surgical management of facial basal cell carcinoma and procedures for plastic reconstruction]. Mund Kiefer Gesichtschir; 2005 Jul;9(4):220-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experiences with surgical management of facial basal cell carcinoma and procedures for plastic reconstruction].
  • BACKGROUND: No recurrences and optimal aesthetic outcomes after R0 resection and plastic reconstruction of the face are the goals in the surgical treatment of basal cell carcinoma.
  • PATIENTS AND METHODS: This study included 205 follow-up patients undergoing R0 resection of primary basal cell carcinoma and facial skin reconstruction between 1998 and 2002; data were analyzed retrospectively.
  • RESULTS: The most frequent locations of basal cell carcinoma were the nasal (40.5%) and orbital (22.9%) regions.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Postoperative Complications / etiology. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15991049.001).
  • [ISSN] 1432-9417
  • [Journal-full-title] Mund-, Kiefer- und Gesichtschirurgie : MKG
  • [ISO-abbreviation] Mund Kiefer Gesichtschir
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


19. Farhadi M, Kamrava SK, Behzadi AH, Rafiezadeh P, Asghari A, Rezvan F, Maleki S: The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma. J Drugs Dermatol; 2010 Feb;9(2):122-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of photodynamic therapy in treatment of recurrent squamous cell and basal cell carcinoma.
  • OBJECTIVES: A number of investigations have already been carried out to assess the effect of photodynamic therapy (PDT) on primary basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) lesions, but lack of investigations on recurrent lesions or lesions with treatment failure, prompted the authors to carry out this study.
  • [MeSH-major] Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy


20. Blázquez-Sánchez N, de Troya-Martín M, Frieyro-Elicegui M, Fúnez-Liébana R, Martín-Márquez L, Rivas-Ruiz F: [Cost analysis of Mohs micrographic surgery in high-risk facial basal cell carcinoma]. Actas Dermosifiliogr; 2010 Sep;101(7):622-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cost analysis of Mohs micrographic surgery in high-risk facial basal cell carcinoma].
  • [Transliterated title] Análisis de costes de la cirugía micrográfica de Mohs en el carcinoma basocelular facial de alto riesgo.
  • INTRODUCTION: Mohs micrographic surgery (MMS) is the treatment of choice for high-risk facial basal cell carcinoma (BCC) as it offers the greatest chance of cure with maximum preservation of healthy tissue.
  • RESULTS: Seventy-nine patients (mean age, 62 years) with 81 high-risk facial BCCs, 97.5% of which were primary tumors, underwent MMS.
  • [MeSH-major] Carcinoma, Basal Cell / economics. Carcinoma, Basal Cell / surgery. Facial Neoplasms / economics. Facial Neoplasms / surgery. Mohs Surgery / economics. Skin Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20858388.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


21. Kilic E, Milde-Langosch K, Müller V, Wirtz R, Ihnen M: [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy]. Pathologe; 2008 Nov;29 Suppl 2:347-52
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
  • [Transliterated title] Expression des "activated leukocyte cell adhesion molecule" im Mammakarzinom. Prädiktivität für das Ansprechen auf eine taxanfreie Chemotherapie.
  • AIMS: Activated leukocyte cell adhesion molecule (ALCAM) is a cell surface immunoglobulin expressed in breast cancer (BC) and is assumed to be implicated in tumourigenesis and tumour progression.
  • MATERIALS AND METHODS: Tissue specimens from 162 primary breast cancer patients were analyzed.
  • RESULTS: In the normal breast ALCAM is expressed in luminal and basal epithelial cells.
  • [MeSH-major] Antigens, CD / genetics. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / genetics. Carcinoma, Ductal / drug therapy. Carcinoma, Ductal / genetics. Carcinoma, Lobular / drug therapy. Carcinoma, Lobular / genetics. Cell Adhesion Molecules, Neuronal / genetics. Fetal Proteins / genetics. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / genetics. Taxoids / administration & dosage
  • [MeSH-minor] Blotting, Western. Breast / pathology. Chemotherapy, Adjuvant. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Kaplan-Meier Estimate. Neoplasm Staging. Oligonucleotide Array Sequence Analysis. Predictive Value of Tests. Prognosis. RNA, Messenger / genetics. Receptors, Estrogen / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18810438.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / ALCAM protein, human; 0 / Antigens, CD; 0 / Cell Adhesion Molecules, Neuronal; 0 / Fetal Proteins; 0 / RNA, Messenger; 0 / Receptors, Estrogen; 0 / Taxoids
  •  go-up   go-down


22. Martorell-Calatayud A, Requena-Caballero C, Botella-Estrada R, Almenar-Medina S, Sanmartín-Jiménez O, Llombart-Cussac B, Nagore-Enguídanos E, Serra-Guillén C, Echeverría-García B, Guillén-Barona C: [Microcystic adnexal carcinoma: Mohs micrographic surgery as the treatment of choice]. Actas Dermosifiliogr; 2009 Oct;100(8):693-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Microcystic adnexal carcinoma: Mohs micrographic surgery as the treatment of choice].
  • [Transliterated title] Carcinoma anexial microquístico: la cirugía micrográfica de Mohs como tratamiento de elección.
  • INTRODUCTION AND OBJECTIVES: Microcystic adnexal carcinoma is a rare and aggressive tumor that manifests clinically as a subcutaneous nodule located on the head or neck.
  • The tumor can be confused clinically and histologically with other benign and malignant skin lesions, often leading to inappropriate initial treatment.
  • The chief concern with microcystic adnexal carcinoma is the elevated morbidity and the high rate of recurrence after wide local excision.
  • MATERIAL AND METHODS: We reviewed the medical histories of 6 consecutive patients with microcystic adnexal carcinoma who underwent Mohs micrographic surgery in our dermatology department between 1995 and 2007.
  • RESULTS: In all cases, lesions were located on the head and were primary tumors.
  • Seventy percent of the tumors were wrongly diagnosed initially as basal cell carcinoma.
  • CONCLUSIONS: The absence of perineural involvement and substantial cell atypia can be attributed to the lesions being primary tumors.
  • This would provide a rationale for definitive radical treatment of the primary tumor from the outset to avoid the complications associated with recurrence.
  • The site and the absence of recurrence in all our patients who underwent Mohs micrographic surgery support the use of this technique as the treatment of choice in microcystic adnexal carcinoma.
  • [MeSH-major] Carcinoma / surgery. Facial Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19775547.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


23. Fukunaga M: Cutaneous spindle cell carcinoma following basal cell carcinoma. Am J Dermatopathol; 2005 Feb;27(1):17-20
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous spindle cell carcinoma following basal cell carcinoma.
  • A spindle cell carcinoma arose three years after the seeming excision of a so-called "infiltrative" basal cell carcinoma (IBCC) in the cheek of an 87-year-old Japanese woman.
  • The patient died after a local recurrence with metastatic lesions in the lung and the neck lymph nodes that were indicated by CT scanning and MRI at nine months after diagnosis.
  • This case and others support the concept that spindle cell carcinoma can pursue an aggressive clinical course.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basal Cell / pathology. Neoplasms, Second Primary. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Dermatopathol. 2005 Dec;27(6):546; author reply 546 [16314711.001]
  • (PMID = 15677971.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin; 68238-35-7 / Keratins
  •  go-up   go-down


24. Belliveau MJ, Coupal DJ, Brownstein S, Jordan DR, Prokopetz R: Infundibulocystic basal cell carcinoma of the eyelid in basal cell nevus syndrome. Ophthal Plast Reconstr Surg; 2010 May-Jun;26(3):147-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infundibulocystic basal cell carcinoma of the eyelid in basal cell nevus syndrome.
  • PURPOSE: To describe the histopathologic findings in a series of eyelid basal cell carcinomas removed from patients with basal cell nevus syndrome.
  • METHODS: Retrospective case series of 5 patients with basal cell nevus syndrome identified from our oculoplastics service.
  • The pertinent published literature on basal cell nevus syndrome and eyelid basal cell carcinoma was reviewed.
  • Twenty-three of these lesions were basal cell carcinomas.
  • The infundibulocystic variant of basal cell carcinoma was identified most commonly (57%).
  • CONCLUSIONS: Eyelid basal cell carcinomas in patients with basal cell nevus syndrome were commonly of the infundibulocystic variety in our series.
  • Infundibulocystic basal cell carcinomas, which can be clinically indistinguishable from the more common forms, are thought to be less aggressive than other types of basal cell carcinoma and are a reassuring histopathologic diagnosis.
  • It is important for the ophthalmologist and pathologist to be aware of infundibulocystic basal cell carcinomas, as they are more common in patients with basal cell nevus syndrome and may be a clue to the diagnosis of this autosomal dominant cancer-predisposition syndrome or other associated syndromes.
  • To our knowledge, this variant of basal cell carcinoma has not been previously discussed in the ophthalmic literature.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology


25. Proia AD, Selim MA, Reutter JC, Michon JJ: Basal cell-signet-ring squamous cell carcinoma of the eyelid. Arch Pathol Lab Med; 2006 Mar;130(3):393-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell-signet-ring squamous cell carcinoma of the eyelid.
  • Excisional biopsy disclosed a neoplasm arising from the epidermis composed of adjoining basal cell and signet-ring squamous cell carcinoma, without a transition zone.
  • The cells comprising the basal and squamous cell carcinomas were distinct immunophenotypically, with only the basal cell carcinoma reacting with Ber-EP4 and CAM 5.2 antibodies.
  • To our knowledge, this case represents the first example of a collision tumor composed of basal cell and signet-ring squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Signet Ring Cell / pathology. Carcinoma, Squamous Cell / pathology. Eyelid Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biomarkers / analysis. Biomarkers, Tumor / analysis. Female. Humans. Keratins / analysis. Neoplasms, Multiple Primary. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Signet ring cell carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16519572.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / human epithelial antigen-125; 68238-35-7 / Keratins
  •  go-up   go-down


26. Arshad AR, Azman WS, Kreetharan A: Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma. Head Neck; 2008 Apr;30(4):544-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary sebaceous nevus of Jadassohn complicated by squamous cell carcinoma and basal cell carcinoma.
  • Its association with basal cell carcinoma is well known.
  • METHOD: This is a case report of sebaceous carcinoma complicated by both basal cell carcinoma and squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Sebaceous of Jadassohn / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Fatal Outcome. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Surgical Flaps

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17972311.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Kuroda N, Fujishima N, Inoue K, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH: Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas. Med Mol Morphol; 2008 Jun;41(2):117-20
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal-like carcinoma of the breast: further evidence of the possibility that most metaplastic carcinomas may be actually basal-like carcinomas.
  • Some investigators have previously suggested that basal-like carcinoma may consist of components of invasive ductal carcinoma, not otherwise specified, metaplastic carcinoma, and medullary carcinoma.
  • We report here two cases of breast carcinoma showing basal cell/myoepithelial differentiation.
  • Additionally, chondroid matrix was observed in the metastatic lesion of the first case and the primary lesion of the second case.
  • [MeSH-major] Breast Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Neoplasm Metastasis / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592167.001).
  • [ISSN] 1860-1480
  • [Journal-full-title] Medical molecular morphology
  • [ISO-abbreviation] Med Mol Morphol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


28. Allali J, D'Hermies F, Renard G: Basal cell carcinomas of the eyelids. Ophthalmologica; 2005 Mar-Apr;219(2):57-71

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas of the eyelids.
  • Basal cell carcinomas (BCC) are the more frequent malignant tumors seen in France as in other western countries.
  • Recurrences are more aggressive, infiltrative and destructive and have a considerably poorer rate of cure than primary tumors.
  • [MeSH-major] Carcinoma, Basal Cell. Eyelid Neoplasms
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Incidence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15802929.001).
  • [ISSN] 0030-3755
  • [Journal-full-title] Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde
  • [ISO-abbreviation] Ophthalmologica
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 141
  •  go-up   go-down


29. Bechert CJ, Stern JB: Basal cell carcinoma with perineural invasion: reexcision perineural invasion? J Cutan Pathol; 2010 Mar;37(3):376-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma with perineural invasion: reexcision perineural invasion?
  • BACKGROUND: Perineural invasion (PI) in basal cell and squamous cell carcinomas, especially of the head and neck, has been reported to indicate an increased morbidity.
  • Reexcision perineural invasion (RPI), a benign mimic of tumoral perineural invasion, may present a difficult histologic differential diagnosis.
  • METHODS: We surveyed the medical literature for PI occurring in basal cell carcinomas to investigate the degree to which the reported cases occurred in reexcision specimens vs. primary biopsy specimens.
  • RESULTS: We found large retrospective studies of 14,120 basal cell carcinomas evaluated for PI in which 310 cases of PI were identified (2.2%), and 20 sporadic case reports of basal cell carcinomas with PI.
  • Of 310 cases of basal cell carcinoma with PI, 196 (63%) were in reexcision specimens.
  • CONCLUSION: The high percentage of PI occurring in reexcision specimens vs. primary excisions may indicate that many of the reported cases of basal cell carcinomas with PI are actually examples of RPI.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Invasiveness / pathology. Neoplasm Seeding. Skin Neoplasms / pathology
  • [MeSH-minor] Biopsy. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Humans. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):76-7 [20840330.001]
  • [CommentIn] J Cutan Pathol. 2012 Nov;39(11):1047-8 [22830947.001]
  • [CommentIn] J Cutan Pathol. 2011 Jan;38(1):78-9 [20860728.001]
  • (PMID = 19615028.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


30. King R, Lyons J, Meyers AL, Googe PB, Page RN, Gupta VK: Primary invasive melanoma and basal cell carcinoma (collision tumor) with blue nevus-like cutaneous metastases. J Cutan Pathol; 2007 Aug;34(8):629-33
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary invasive melanoma and basal cell carcinoma (collision tumor) with blue nevus-like cutaneous metastases.
  • The juxtaposition of malignant melanoma and basal cell carcinoma (BCC) has been rarely reported in case reports, with most cases describing melanoma in situ and BCC.
  • Immunohistochemical studies delineated the two cell populations.
  • The metastases occurred in the same anatomical region as the primary tumor, and histologically consisted of pigmented dendritic melanocytes and melanophages in the superficial and mid-dermis and arranged in a blue nevus-like lesion.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Blue / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy. Humans. Lymphocytes / pathology. Male. Melanocytes / pathology. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Nevus.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640233.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


31. Blanchard E, Wierzbicka-Hainaut E, Thellier S, Dupeyron F, Guillet G: [Infiltrative basal cell carcinoma presenting as chronic leg ulcer]. Ann Dermatol Venereol; 2010 Mar;137(3):216-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Infiltrative basal cell carcinoma presenting as chronic leg ulcer].
  • BACKGROUND: Basal cell carcinoma is the most common carcinoma of the skin and is usually found on the head and neck.
  • We report an unusual case of basal cell carcinoma presenting as a chronic leg ulcer, with underlying bone involvement.
  • Histological examination revealed infiltrative basal cell carcinoma.
  • Treatment consisted of surgical excision of 80% of the primary lesion and coverage with a split-thickness skin graft.
  • Examination of the surgical piece revealed invasion of bone by the carcinoma.
  • DISCUSSION: There is a need for awareness among all doctors of the clinical signs evocative of malignant transformation of a leg ulcer so that a skin biopsy may be performed for suspicious ulcers.
  • Our case is distinguished by the underlying invasion of bone by basal cell carcinoma, as attested by imaging and histology.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Leg Ulcer / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Leg Bones / pathology. Leg Bones / surgery. Neoplasm Invasiveness / pathology

  • MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20227566.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


32. Thakur S, Chalioulias K, Hayes M, While A: Bilateral primary Merkel cell carcinoma of the upper lid misdiagnosed as Basal cell carcinoma. Orbit; 2008;27(2):139-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral primary Merkel cell carcinoma of the upper lid misdiagnosed as Basal cell carcinoma.
  • Merkel cell tumour is a rare primary malignant tumour of the skin that can affect the lids and periocular region.
  • Clinically, it is difficult to distinguish from other malignancies and the diagnosis requires careful histological analysis and immunocytochemical staining.
  • A case of Merkel cell tumour affecting the lids and originally misdiagnosed is presented.
  • Correct diagnosis was made only after the appearance of a second Merkel cell tumour on the contralateral lid.
  • [MeSH-major] Carcinoma, Merkel Cell / diagnosis. Eyelid Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Carcinoma, Basal Cell / diagnosis. Diagnosis, Differential. Diagnostic Errors. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18415877.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Kimyai-Asadi A, Alam M, Goldberg LH, Peterson SR, Silapunt S, Jih MH: Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas. J Am Acad Dermatol; 2005 Sep;53(3):464-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of narrow-margin excision of well-demarcated primary facial basal cell carcinomas.
  • BACKGROUND: A 4-mm surgical margin of clinically normal skin is the current standard for elliptical excision of basal cell carcinomas (BCCs).
  • METHODS: A total of 134 primary, small (<1 cm), well-demarcated, facial nodular BCCs were excised as an ellipse with 1-, 2-, or 3-mm margins around the visible border of the tumor.
  • CONCLUSION: Narrow margins (1-3 mm) are inadequate for the excision of small, well-demarcated, primary nodular BCCs of the face.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Head and Neck Neoplasms / surgery. Mohs Surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112354.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Li N, Wolgamot G, Argenyi Z: Primary cutaneous neuroendocrine cell carcinoma (Merkel cell carcinoma) with prominent microcystic features, mimicking eccrine carcinoma. J Cutan Pathol; 2007 May;34(5):410-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous neuroendocrine cell carcinoma (Merkel cell carcinoma) with prominent microcystic features, mimicking eccrine carcinoma.
  • Although primary cutaneous neuroendocrine cell carcinoma [Merkel cell carcinoma (MCC)] may show divergent features, including microcystic ('tubuloglandular'), squamous, eccrine and rhabdomyoblastic, a diffuse microcystic pattern is exceedingly rare.
  • In this study, we present two cases of MCC with prominent microcystic features, which precluded a definitive diagnosis in the initial punch biopsy.
  • Punch biopsies from both patients revealed an infiltrating neoplasm with prominent microcystic features that mimick tubuloglandular structures, lined by hyperchromatic basaloid cells, which were strongly positive for chromogranin and BerEP4, variably positive for CK7 and CK5/6 and negative for CK20, synaptophysin, S-100, epithelial membrane antigen (EMA), gross cystic disease fluid protein-15 (GCDFP-15), estrogen/progesterone receptors (ER/PR), thyroid transcription factor 1 (TTF1) and carcinoembryonic antigen (CEA).
  • Although the lack of CK20 staining is unusual, the histologic characteristics along with the remaining immunohistochemical studies favor the diagnosis of a primary cutaneous neuroendocrine cell carcinoma over the variants of eccrine carcinoma or basal cell carcinoma with neuroendocrine differentiation.
  • [MeSH-major] Carcinoma, Merkel Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Diagnosis, Differential. Eccrine Glands / pathology. Humans. Immunohistochemistry. Male. Neck / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17448197.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Chai L, Tang J: [Analysis of 41 cases of basal cell carcinoma in maxillofacial area]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Apr;20(7):297-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 41 cases of basal cell carcinoma in maxillofacial area].
  • OBJECTIVE: To explore the incidence, location and relationship between surgical margin and metastasis of basal cell carcinoma (BCC) in maxillofacial area.
  • RESULT: From 1996 to 2003, there were 41 cases of primary BBC in maxillofacial region, of whom 17 were males and 24 were females (male-to-female ratio, 1:1.41).
  • [MeSH-major] Carcinoma, Basal Cell. Facial Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16780141.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


36. Naumann IC, Cordes SR: Giant basal cell carcinoma of the forehead with extensive intracranial involvement. Ann Otol Rhinol Laryngol; 2007 Sep;116(9):663-6
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant basal cell carcinoma of the forehead with extensive intracranial involvement.
  • Basal cell carcinoma (BCC) is the most common malignant skin lesion and is frequently curatively treated with local excision.
  • Despite its fairly benign growth pattern, BCC should never be underestimated, and care should be taken not only in the complete primary excision but also in cancer surveillance.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Forehead. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / methods. Reconstructive Surgical Procedures / methods. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926588.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Gudi V, Ormerod AD, Dawn G, Green C, MacKie RM, Douglas WS, Gupta G, Scottish Dermatological Society: Management of basal cell carcinoma by surveyed dermatologists in Scotland. Clin Exp Dermatol; 2006 Sep;31(5):648-52
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of basal cell carcinoma by surveyed dermatologists in Scotland.
  • BACKGROUND: The British Association of Dermatologists (BAD) has produced guidelines for management of basal cell carcinoma (BCC) in the UK.
  • OBJECTIVES: Our primary objectives were to assess the management of BCCs in Scotland and to compare it with BAD guidelines.
  • A diagnostic biopsy was taken in 22% of lesions, and the rest were treated definitively after a clinical diagnosis of BCC, of which 90% were confirmed on histology.
  • [MeSH-major] Carcinoma, Basal Cell. Skin Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16901303.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


38. Betti R, Menni S, Radaelli G, Bombonato C, Crosti C: Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas. J Dermatol; 2010 Jul;37(7):611-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Micronodular basal cell carcinoma: a distinct subtype? Relationship with nodular and infiltrative basal cell carcinomas.
  • Micronodular basal cell carcinoma (BCC) may be more difficult to eradicate and prone to recurrence than nodular subtype.
  • The aim of the study was to compare anatomical and histological characteristics of the basal cell carcinomas subtypes and the relationship of the micronodular BCC with other subtypes.
  • Primary BCCs (n = 3074) were classified as superficial, nodular, micronodular, morpheic/infiltrative.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Nose Neoplasms / pathology. Scalp / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629826.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


39. Foley P, Freeman M, Menter A, Siller G, El-Azhary RA, Gebauer K, Lowe NJ, Jarratt MT, Murrell DF, Rich P, Pariser DM, Oseroff AR, Barnetson R, Anderson C, Kossard S, Gibson LE, Tope WD: Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies. Int J Dermatol; 2009 Nov;48(11):1236-45
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy with methyl aminolevulinate for primary nodular basal cell carcinoma: results of two randomized studies.
  • BACKGROUND: Data suggest that photodynamic therapy using topical methyl aminolevulinate (MAL PDT) may be a noninvasive alternative to excisional surgery for nodular basal cell carcinoma (BCC).
  • In the studies described here, we investigated the histologic response, tolerability, and cosmetic outcome with MAL PDT for primary nodular BCC (<or= 5 mm in depth).
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20064185.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


40. Harwood M, Wu H, Tanabe K, Bercovitch L: Metastatic basal cell carcinoma diagnosed by sentinel lymph node biopsy. J Am Acad Dermatol; 2005 Sep;53(3):475-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma diagnosed by sentinel lymph node biopsy.
  • Although commonly used in the treatment of melanoma, sentinel lymph node biopsy has not yet been successfully used to detect lymphatic metastasis of basal cell carcinoma because of exceedingly low rates of metastasis.
  • We describe the use of lymphatic mapping and sentinel lymph node biopsy in a patient after basal cell carcinoma was identified within a lymphatic vessel in the primary excisional specimen.
  • As a result, the patient was found to have clusters of basal cell carcinoma in a sentinel lymph node resected from the right deltopectoral groove.
  • Although metastatic basal cell carcinoma is exceedingly rare, we conclude that sentinel lymph node biopsy may be useful for certain high-risk lesions, such as lesions demonstrating histologic evidence of lymphatic invasion.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / secondary. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16112356.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 556Q0P6PB1 / Technetium Tc 99m Sulfur Colloid
  •  go-up   go-down


41. Tévar E, Torrelo A, Contreras F, Colmenero I, Zambrano A: [Multiple basal cell carcinomas on phacomatosis pigmentokeratotica]. Actas Dermosifiliogr; 2006 Oct;97(8):518-21
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple basal cell carcinomas on phacomatosis pigmentokeratotica].
  • We present a patient with phacomatosis pigmentokeratotica (PPK) who developed several basal cell carcinomas on epidermal nevus lesions in adult life.
  • PPK shows an elevated incidence of development of malignant lesions both on the sebaceous or epidermal nevus component as well as on the nevus spilus one.
  • [MeSH-major] Carcinoma, Basal Cell. Neoplasms, Multiple Primary. Neurocutaneous Syndromes. Skin Neoplasms

  • Genetic Alliance. consumer health - Phacomatosis pigmentokeratotica.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067530.001).
  • [ISSN] 0001-7310
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


42. Bhattacharjee P, Leffell D, McNiff JM: Primary cutaneous carcinosarcoma arising in a patient with nevoid basal cell carcinoma syndrome. J Cutan Pathol; 2005 Oct;32(9):638-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous carcinosarcoma arising in a patient with nevoid basal cell carcinoma syndrome.
  • BACKGROUND: Nevoid basal cell carcinoma syndrome (NBCC) is an autosomal dominant disorder characterized by developmental abnormalities and neoplasms including basal cell carcinoma (BCC) and sarcomas (i.e. leiomyosarcoma, rhabdomyosarcoma, and fibrosarcoma).
  • Primary cutaneous carcinosarcoma (PCC), a rare tumor composed of malignant epithelial and mesenchymal components, has never been previously described in association with this syndrome.
  • CONCLUSIONS: Several carcinosarcomas have been reported to contain BCC as the malignant epithelial component, but to our knowledge, this is the first report of PCC associated with NBCC.
  • Primary cutaneous carcinosarcoma arising in a patient with nevoid basal cell carcinoma syndrome.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevoid basal cell carcinoma syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16176303.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


43. Levy J, Cagnano E, Benharroch D, Monos T, Lifshitz T: Collision sebaceous and basal cell carcinomas of the eyelid. Ann Diagn Pathol; 2006 Jun;10(3):157-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision sebaceous and basal cell carcinomas of the eyelid.
  • OBJECTIVE: To report a rare case of collision sebaceous and basal cell carcinomas of the eyelid.
  • Histopathology showed mixed sebaceous as well as basal cell carcinoma with uninvolved surgical margins.
  • CONCLUSION: Sebaceous and basal cell carcinomas can coexist in the eyelid within the same clinical lesion.
  • Because of the potential risk of metastasis of sebaceous carcinoma, close follow-up of the patients is advisable.
  • [MeSH-major] Adenocarcinoma, Sebaceous / pathology. Carcinoma, Basal Cell / pathology. Eyelid Neoplasms / pathology. Neoplasms, Multiple Primary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16730311.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


44. Braun-Falco M: Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type. J Cutan Pathol; 2007 Sep;34(9):731-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined malignant melanoma and basal cell carcinoma tumor of the intermingled type.
  • BACKGROUND: The combination of malignant melanoma (MM) and basal cell carcinoma (BCC) within a single tumor is an unusual finding.
  • CONCLUSION: By reviewing the low number of published cases, we found that a combined MM-BCC tumor exists in two variants: a collision type in which components of each cell type are clearly demarcated and an intermingled type in which both cell types grow intimately together.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17696923.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


45. Bigby SM, Charlton A, Miller MV, Zwi LJ, Oliver GF: Biphasic sarcomatoid basal cell carcinoma (carcinosarcoma): four cases with immunohistochemistry and review of the literature. J Cutan Pathol; 2005 Feb;32(2):141-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biphasic sarcomatoid basal cell carcinoma (carcinosarcoma): four cases with immunohistochemistry and review of the literature.
  • BACKGROUND: Biphasic sarcomatoid carcinoma (BSC), or carcinosarcoma, is an uncommon biphasic neoplasm that has been reported in diverse anatomical sites.
  • The tumor is composed of a malignant epithelial component intimately associated with a malignant mesenchymal component, which may be homologous or heterologous.
  • Twenty-three cases of primary cutaneous BSC have been reported in the English literature.
  • In only eight of these cases was basal cell carcinoma the epithelial component.
  • METHODS: We report a further four cases of primary cutaneous biphasic basal cell carcinoma, and include the clinical, histological and immunohistochemical features.
  • RESULTS: The four cases showed basal cell carcinoma associated with a pleomorphic sarcomatous stroma.
  • [MeSH-minor] Aged. Aged, 80 and over. Antigens, CD / metabolism. Cell Adhesion Molecules / metabolism. Female. Humans. Immunohistochemistry. Male. Tumor Suppressor Protein p53 / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606673.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Tumor Suppressor Protein p53; 0 / Vimentin
  •  go-up   go-down


46. Ramachandran S, Rajaratnam R, Smith AG, Lear JT, Strange RC: Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma. J Am Acad Dermatol; 2009 Aug;61(2):247-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with both basal and squamous cell carcinomas are at a lower risk of further basal cell carcinomas than patients with only a basal cell carcinoma.
  • BACKGROUND: The rate of development of further basal cell carcinoma (BCC) after first presentation is highly variable.
  • OBJECTIVE: We assessed the risks of developing a subsequent BCC in patients who developed a BCC and a squamous cell carcinoma (SCC) and compared them with patients who developed a BCC only.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Neoplasm Recurrence, Local / epidemiology. Neoplasms, Multiple Primary / epidemiology
  • [MeSH-minor] Age Distribution. Aged. Aged, 80 and over. Cohort Studies. Confidence Intervals. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Neoplasm Staging. Odds Ratio. Probability. Prognosis. Risk Assessment. Sex Distribution

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19481292.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Lyle P, Nakamura K, Togerson S: Lymphoepithelioma-like carcinoma arising in the scar from a previously excised basal cell carcinoma. J Cutan Pathol; 2008 Jun;35(6):594-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoepithelioma-like carcinoma arising in the scar from a previously excised basal cell carcinoma.
  • We report a case of a primary lymphoepithelioma-like carcinoma of the skin (LELCS) associated with scar from a previous excision of basal cell carcinoma.
  • The patient had a history of a basal cell carcinoma in the same location, which was completely excised 1 year earlier.
  • Retrospective review of the original excision specimen confirmed the diagnosis of an ordinary basal cell carcinoma.
  • [MeSH-major] Carcinoma / complications. Carcinoma, Basal Cell / pathology. Cicatrix / complications. Neoplasms, Second Primary / complications. Skin Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18201243.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 68238-35-7 / Keratins
  •  go-up   go-down


48. Ting PT, Kasper R, Arlette JP: Metastatic basal cell carcinoma: report of two cases and literature review. J Cutan Med Surg; 2005 Jan;9(1):10-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: report of two cases and literature review.
  • BACKGROUND: Metastatic basal cell carcinoma (MBCC) is defined as primary cutaneous basal cell carcinoma (BCC) that spreads to distant sites as histologically similar metastatic deposits of BCC.
  • METHODS: This article examines two cases of MBCC and provides a literature review of risk factors inherent in epidemiology, patient demographics, and the clinicohistopathological characteristics of primary and metastatic BCC lesions.
  • Patients with MBCC often begin with long-standing primary BCC lesions that are either large or recurrent after treatment.
  • CONCLUSION: These case reports and review provide important diagnostic and management considerations for primary BCC and MBCC.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / therapy. Facial Neoplasms / pathology. Facial Neoplasms / therapy
  • [MeSH-minor] Fatal Outcome. Female. Humans. Male. Middle Aged. Mohs Surgery. Neoplasm Metastasis. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16208438.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


49. Chen CH, Rowlands C, Sengupta SK, George RL, Parulekar W, Thain K, O'Malley F, Isotalo PA: Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ. Breast J; 2009 Jul-Aug;15(4):409-13
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary basaloid carcinoma of the nipple with associated squamous cell carcinoma in situ.
  • We describe a primary invasive adenocarcinoma of the nipple with extensive basaloid features that was also associated with squamous cell carcinoma (SCC) in situ and an aggressive behavior.
  • The differential diagnosis included a primary basaloid adenocarcinoma of the nipple, basal cell carcinoma of the nipple, neuroendocrine carcinoma, melanoma, basaloid variant of adenoid cystic carcinoma and metastatic disease.
  • Immunohistochemical profile of this tumor supported a primary basaloid adenocarcinoma of the nipple.
  • Although the initial sentinel lymph node biopsy was negative, within a year of diagnosis, the patient developed ipsilateral axillary node and pulmonary metastases.
  • To the best of our knowledge, this is the first case of basaloid carcinoma to be documented in this anatomic site.
  • [MeSH-major] Carcinoma in Situ / pathology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / pathology. Nipples / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19601946.001).
  • [ISSN] 1524-4741
  • [Journal-full-title] The breast journal
  • [ISO-abbreviation] Breast J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


50. McGregor DH, Cherian R, Romanas MM, Ulusarac O, Mathur SC, Feldman MM: Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma. Ann Clin Lab Sci; 2008;38(2):157-62
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amelanotic malignant melanoma: two collision tumors presenting as basal cell carcinoma and atypical fibroxanthoma.
  • Collision (contiguous) tumors of the skin can result in misleading clinicopathological presentations, and the choice of appropriate diagnostic techniques may prevent incomplete diagnosis and management.
  • We report 2 cases of collision tumors involving amelanotic malignant melanoma of the back.
  • One patient is a 79-yr-old male with an 8.7 x 5.5 x 4.5 cm polypoid lesion that on shave biopsy was diagnosed as basal cell carcinoma.
  • Subsequent excision showed that the lesion was largely composed of amelanotic melanoma underlying a relatively small and thin basal cell carcinoma, and this probably would have been demonstrated in a punch (rather than shave) biopsy.
  • This lesion was composed of 2 distinct contiguous neoplastic infiltrates, the predominant component being an atypical fibroxanthoma and the smaller component an amelanotic melanoma (primary vs metastatic), with diagnostic confirmation requiring multiple immunohistochemical stains.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Histiocytoma, Benign Fibrous / diagnosis. Melanoma, Amelanotic / diagnosis. Neoplasms, Multiple Primary / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469362.001).
  • [ISSN] 1550-8080
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  •  go-up   go-down


51. Hallock GG, Bulatao IS: Basal cell carcinoma masquerading as a hallux valgus. Can J Plast Surg; 2007;15(1):47-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma masquerading as a hallux valgus.
  • The incidence of primary skin cancers of the foot is exceedingly low; conversely, problems associated with a hallux valgus are common.
  • Ultimately, a shave biopsy revealed that the lesion was a basal cell carcinoma.
  • Basal cell carcinoma associated with a hallux valgus has not been previously reported, and this reinforces the concept that malignant degeneration as the cause of any chronic ulceration should not be overlooked.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 2004 Apr 1;113(4):1297-9 [15083055.001]
  • [Cites] Plast Reconstr Surg. 2004 Mar;113(3):1101-3 [15108936.001]
  • [Cites] Plast Reconstr Surg. 1995 Jan;95(1):199-200 [7809242.001]
  • [Cites] Ann Plast Surg. 1990 Feb;24(2):186-8 [2316978.001]
  • [Cites] Clin Podiatr Med Surg. 1993 Jan;10(1):79-95 [8431842.001]
  • [Cites] J Am Podiatry Assoc. 1978 Oct;68(10):693-5 [690378.001]
  • (PMID = 19554132.001).
  • [ISSN] 1195-2199
  • [Journal-full-title] The Canadian journal of plastic surgery = Journal canadien de chirurgie plastique
  • [ISO-abbreviation] Can J Plast Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2686046
  • [Keywords] NOTNLM ; Basal cell carcinoma / Hallux valgus / Skin cancer
  •  go-up   go-down


52. Geist DE, Garcia-Moliner M, Fitzek MM, Cho H, Rogers GS: Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management. Dermatol Surg; 2008 Dec;34(12):1642-51
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perineural invasion of cutaneous squamous cell carcinoma and basal cell carcinoma: raising awareness and optimizing management.
  • BACKGROUND: Perineural invasion (PNI) by cutaneous squamous cell carcinoma (CSCC) and basal cell carcinoma (BCC) is an infrequent but not rare complication of traditionally low-morbidity skin cancers that can lead to catastrophic sequelae; 2.5% to 14% of CSCC and approximately 3% of BCC exhibit PNI.
  • [MeSH-major] Bell Palsy / etiology. Carcinoma, Basal Cell / complications. Carcinoma, Basal Cell / therapy. Carcinoma, Squamous Cell / complications. Carcinoma, Squamous Cell / therapy. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / therapy. Skin Neoplasms / complications. Skin Neoplasms / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Mohs Surgery. Neoplasm Invasiveness. Peripheral Nerves

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Bell's Palsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19018830.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Wu JK, Oh C, Strutton G, Siller G: An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma. Australas J Dermatol; 2006 Feb;47(1):46-8
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An open-label, pilot study examining the efficacy of curettage followed by imiquimod 5% cream for the treatment of primary nodular basal cell carcinoma.
  • SUMMARY The short-term efficacy of imiquimod 5% cream for the treatment of primary superficial basal cell carcinoma has been established.
  • This study investigated its efficacy following curettage (without electrodesiccation) for the treatment of primary nodular basal cell carcinoma on the trunk and limbs.
  • Three months post treatment all lesions were excised, and 32 of 34 treated lesions (94%) were histologically clear of basal cell carcinoma.
  • Curettage followed by imiquimod 5% cream is effective for the treatment of primary nodular basal cell carcinoma on the trunk and limbs, and most patients are pleased with the cosmetic outcome.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Administration, Topical. Adult. Aged. Biopsy, Needle. Combined Modality Therapy. Curettage / methods. Emollients / therapeutic use. Female. Follow-Up Studies. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Pilot Projects. Risk Assessment. Single-Blind Method. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405483.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Emollients; 99011-02-6 / imiquimod
  •  go-up   go-down


54. Segerbäck D, Strozyk M, Snellman E, Hemminki K: Repair of UV dimers in skin DNA of patients with basal cell carcinoma. Cancer Epidemiol Biomarkers Prev; 2008 Sep;17(9):2388-92
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repair of UV dimers in skin DNA of patients with basal cell carcinoma.
  • Epidemiologic studies suggest that exposure to sunlight is the primary etiologic agent for basal cell carcinoma.
  • In this study, repair of photoproducts in DNA was followed in the skin of patients with basal cell carcinoma and control subjects.
  • The levels of TT=T in patients with basal cell carcinoma and controls were similar (9.9 +/- 4.0 and 9.2 +/- 2.9 products per 10(6) normal nucleotides), whereas the level of TT=C was significantly lower in controls than in patients with basal cell carcinoma (6.2 +/- 3.1 versus 10.9 +/- 4.5 products per 10(6) normal nucleotides).
  • The fractions of TT=T remaining after 24 hours and 3 weeks were significantly higher in patients with basal cell carcinoma (72% and 11%) compared with controls (48% and 5%).
  • A slower removal in patients with basal cell carcinoma than in controls was indicated also for TT=C (52% versus 42% remaining at 24 hours); however, the difference between groups was not significant.
  • When including data from our previously reported small-scale study, the fraction of dimers remaining at 24 hours was significantly higher in patients with basal cell carcinoma for both TT=C and TT=T.
  • The data suggest that patients with basal cell carcinoma have a reduced capacity to repair UV-induced DNA lesions.
  • [MeSH-major] Carcinoma, Basal Cell / chemistry. DNA Repair. DNA, Neoplasm / metabolism. Pyrimidine Dimers / metabolism. Skin / radiation effects. Skin Neoplasms / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18768508.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Pyrimidine Dimers
  •  go-up   go-down


55. Khandwala MA, Lalchan SA, Chang BY, Habib M, Chakrabarty A, Cassells-Brown A: Outcome of periocular basal cell carcinoma managed by overnight paraffin section. Orbit; 2005 Dec;24(4):243-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of periocular basal cell carcinoma managed by overnight paraffin section.
  • RESULTS: This study yielded 93 basal cell carcinomas (BCCs) of which 86 were of primary origin and 7 were recurrent tumours.
  • Overall histological clearance for primary BCCs was achieved in 81/86 (94.2%) cases.
  • CONCLUSION: For primary BCCs the recurrence rate in this study was low and comparable to that following Mohs' technique.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Paraffin Embedding / methods
  • [MeSH-minor] Aged. Female. Humans. Male. Neoplasm Recurrence, Local / surgery. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354633.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


56. Pincus LB, McCalmont TH, Neuhaus IM, Kasper R, Oh DH: Basal cell carcinomas arising within multiple trichoepitheliomas. J Cutan Pathol; 2008 Oct;35 Suppl 1:59-64
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinomas arising within multiple trichoepitheliomas.
  • Biopsies from multiple lesions showed TEs both alone and associated with basal cell carcinoma (BCC) in the same section, suggesting the secondary development of BCCs within TEs.
  • Awareness of the potential for the evolution of carcinoma in patients with MFT is important in the management of these patients.
  • [MeSH-major] Carcinoma / pathology. Carcinoma, Basal Cell / pathology. Neoplasms, Adnexal and Skin Appendage / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright Blackwell Munksgaard 2008.
  • (PMID = 18544067.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Keratin-20; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


57. Swanson EL, Amdur RJ, Mendenhall WM, Morris CG, Kirwan JM, Flowers F: Radiotherapy for basal cell carcinoma of the medial canthus region. Laryngoscope; 2009 Dec;119(12):2366-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy for basal cell carcinoma of the medial canthus region.
  • OBJECTIVES/HYPOTHESIS: To report outcome for patients treated with radiotherapy (RT) for basal cell carcinoma of the medial canthus.
  • METHODS: Thirty-three patients treated with RT at the University of Florida between 1965 and 2005 for basal cell carcinoma of the medial canthus were retrospectively reviewed.
  • RT was the primary treatment for gross disease in 70% of patients and for positive margin after resection in 30%.
  • Tumor recurred at the primary site in 10%.
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Eyelid Neoplasms / radiotherapy
  • [MeSH-minor] Dose-Response Relationship, Radiation. Follow-Up Studies. Humans. Neoplasm Recurrence, Local. Neoplasm Staging. Retrospective Studies. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19780029.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Asuquo ME, Agweye P, Ugare G, Ebughe G: Basal cell carcinoma in five albino Africans from the south-eastern equatorial rain forest of Nigeria. Int J Dermatol; 2007 Jul;46(7):754-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma in five albino Africans from the south-eastern equatorial rain forest of Nigeria.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common cutaneous malignancy in the white population and occurs infrequently in dark-pigmented individuals.
  • METHODS: We evaluated the clinical histories and treatment outcomes of patients with a histologic diagnosis of BCC, who were seen at the University of Calabar Teaching Hospital, Calabar, Nigeria between January 2000 and December 2004.
  • Lesions were removed by excision with primary closure, except for large fleshy tumors that were treated by excision and electrocautery.
  • [MeSH-major] Albinism / complications. Carcinoma, Basal Cell / etiology. Skin Neoplasms / etiology. Ultraviolet Rays / adverse effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17614810.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Caekelbergh K, Nikkels AF, Leroy B, Verhaeghe E, Lamotte M, Vincent R: Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes. J Drugs Dermatol; 2009 Nov;8(11):992-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy using methyl aminolevulinate in the management of primary superficial basal cell carcinoma: clinical and health economic outcomes.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common form of skin cancer worldwide.
  • [MeSH-major] Aminolevulinic Acid / analogs & derivatives. Carcinoma, Basal Cell / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / therapeutic use. Skin Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19894366.001).
  • [ISSN] 1545-9616
  • [Journal-full-title] Journal of drugs in dermatology : JDD
  • [ISO-abbreviation] J Drugs Dermatol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


60. Ferguson MS, Nouraei SA, Davies BJ, McLean NR: Basal cell carcinoma of the nipple-areola complex. Dermatol Surg; 2009 Nov;35(11):1771-5
MedlinePlus Health Information. consumer health - Male Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the nipple-areola complex.
  • BACKGROUND: Basal cell carcinoma (BCC) of the nipple-areola complex is uncommon.
  • CONCLUSIONS: The optimal treatment of this condition should be local excision, but patients with this condition should be followed up for primary site recurrence and axillary metastasis, because there is greater incidence than with BCC at other anatomical sites.
  • [MeSH-major] Breast Neoplasms. Breast Neoplasms, Male. Carcinoma, Basal Cell. Nipples

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19660023.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 32
  •  go-up   go-down


61. Ionescu DN, Arida M, Jukic DM: Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation. Arch Pathol Lab Med; 2006 Jan;130(1):45-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: four case reports, review of literature, and immunohistochemical evaluation.
  • CONTEXT: Metastatic basal cell carcinoma (BCC) is relatively rare and is seldom considered a complication in the routine treatment and follow-up of patients with BCC.
  • RESULTS: In metastasizing BCC, Ki-67 staining was slightly higher in metastatic sites than in primary sites (average 63% and 51%, respectively).
  • p53 was expressed in 3 of 4 primary sites and 2 of 4 metastatic sites.
  • Bcl-2 was positive in both primary and metastatic sites in 3 of 4 cases.
  • [MeSH-major] Carcinoma, Basal Cell / secondary. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Fatal Outcome. Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Male. Neoplasm Metastasis / pathology. Proto-Oncogene Proteins c-bcl-2 / analysis. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390237.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


62. Ceilley RI, Del Rosso JQ: Current modalities and new advances in the treatment of basal cell carcinoma. Int J Dermatol; 2006 May;45(5):489-98
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current modalities and new advances in the treatment of basal cell carcinoma.
  • Basal cell carcinoma (BCC) is one of the most common cancers.
  • Curettage with electrodesiccation is a common method for treating primary BCC.
  • [MeSH-major] Carcinoma, Basal Cell / therapy. Neoplasm Recurrence, Local / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700779.001).
  • [ISSN] 0011-9059
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  • [Number-of-references] 58
  •  go-up   go-down


63. Montgomery L, Macpherson M, Gerig L, Carty K, Fox G, Esche B, Clark BG: Simultaneous treatment of multiple basal cell carcinoma lesions. Br J Radiol; 2008 Dec;81(972):e290-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous treatment of multiple basal cell carcinoma lesions.
  • We present a rare case of advanced basal cell carcinoma where multiple large lesions, located on the anterior chest wall and back, were treated simultaneously using tomotherapy (TomoTherapy HiArt; TomoTherapy Inc, Madison, WI).
  • [MeSH-major] Carcinoma, Basal Cell / radiotherapy. Neoplasms, Multiple Primary / radiotherapy. Skin Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Basal Cell Carcinoma, Multiple.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19029050.001).
  • [ISSN] 1748-880X
  • [Journal-full-title] The British journal of radiology
  • [ISO-abbreviation] Br J Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


64. Lee CL, Hsu SL, Chang CH: Primary ocular caruncular basal cell carcinoma in a Chinese patient. Kaohsiung J Med Sci; 2010 Oct;26(10):562-6
MedlinePlus Health Information. consumer health - Eye Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ocular caruncular basal cell carcinoma in a Chinese patient.
  • Although basal cell carcinoma (BCC) is the most common eyelid neoplasm, BCC that originates from the lacrimal caruncle is extremely rare.
  • To the best of our knowledge, only seven cases have been reported and here we report the first documented primary caruncular BCC in an Oriental patient.
  • Malignant tumors of the caruncle are infrequent.
  • BCC should be considered in the differential diagnosis of a pigmented caruncular lesion.
  • [MeSH-major] Asian Continental Ancestry Group. Carcinoma, Basal Cell / pathology. Eye Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20950783.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


65. Chadha V, Wright M: Small margin excision of periocular basal cell carcinomas. Br J Ophthalmol; 2009 Jun;93(6):803-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small margin excision of periocular basal cell carcinomas.
  • AIMS: To analyse the outcome of small margin (up to 2 mm) excision of primary clinically well-defined periocular basal cell carcinomas (BCCs).
  • METHODS: Retrospective evaluation of 90 well-demarcated primary BCCs having a minimum follow-up of 36 months.
  • In the absence of availability of Mohs surgery, well-demarcated nodular basal cell carcinomas can be safely excised using smaller margins than conventionally practised.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Ophthalmol. 2010 Aug;94(8):1114 [20530178.001]
  • (PMID = 19304655.001).
  • [ISSN] 1468-2079
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Beck B, Lehen'kyi V, Roudbaraki M, Flourakis M, Charveron M, Bordat P, Polakowska R, Prevarskaya N, Skryma R: TRPC channels determine human keratinocyte differentiation: new insight into basal cell carcinoma. Cell Calcium; 2008 May;43(5):492-505
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TRPC channels determine human keratinocyte differentiation: new insight into basal cell carcinoma.
  • Aberrant keratinocyte differentiation is considered to be a key mechanism in the onset of hyperproliferative dermatological diseases, including basal cell carcinoma (BCC).
  • This study was designed to investigate the role of calcium-permeable TRPC channels in human keratinocyte differentiation and BCC, using a combination of molecular and cell biology approaches, involving electrophysiology and Ca(2+)-imaging, on the HaCaT cell line, primary cultures of normal human keratinocytes, and BCC cells.
  • [MeSH-major] Calcium / metabolism. Carcinoma, Basal Cell / metabolism. Keratinocytes / metabolism. Skin Neoplasms / metabolism. TRPC Cation Channels / physiology
  • [MeSH-minor] Cell Differentiation. Cell Line. Down-Regulation. Electric Conductivity. Endoplasmic Reticulum / metabolism. Humans. Patch-Clamp Techniques. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17920677.001).
  • [ISSN] 0143-4160
  • [Journal-full-title] Cell calcium
  • [ISO-abbreviation] Cell Calcium
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / TRPC Cation Channels; 0 / TRPC4 ion channel; 0 / transient receptor potential cation channel, subfamily C, member 1; SY7Q814VUP / Calcium
  •  go-up   go-down


67. Taherian K, Shekarchian M, Atkinson PL: Surgical excision of periocular basal cell carcinomas. Indian J Ophthalmol; 2007 Mar-Apr;55(2):137-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical excision of periocular basal cell carcinomas.
  • The purpose of this study was to determine the histological clearance and clinical recurrence rates following excision of primary periocular biopsy-proven basal cell carcinomas (BCCs) in a teaching hospital in United Kingdom and compare it with other published reports.
  • Records of consecutive patients with a biopsy proven diagnosis of primary periocular BCCs treated surgically at our hospital between 1995 and March 2003 were reviewed.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Ophthalmologic Surgical Procedures / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy. England / epidemiology. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17322605.001).
  • [ISSN] 0301-4738
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


68. Filho LL, de Oliveira de Avelar Alchorne A, Pereira GC, Lopes LR, de Carvalho TC: Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication. Int J Dermatol; 2008 Jun;47(6):610-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histological and immunohistochemical evaluation of basal cell carcinoma following curettage and electrodessication.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most frequent non-melanoma skin cancer.
  • METHODS: 20 primary BCC outpatients were studied at the Dermatology Service of Getúlio Vargas Hospital in the city of Teresina--State of Piauí--Brazil, with lesions of up to 1 cm in diameter on the face, and up to 1.5 cm elsewhere, and with no clinical signs of sclerosing and micronodular forms.
  • CONCLUSIONS: The persistence of tumoral residues after 2 curettage and electrofulguration cycles for basal cell carcinoma was found in 5 sites treated (25%).
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Curettage. Electrosurgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm, Residual. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18477158.001).
  • [ISSN] 1365-4632
  • [Journal-full-title] International journal of dermatology
  • [ISO-abbreviation] Int. J. Dermatol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125
  •  go-up   go-down


69. Saran A: Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling. Future Oncol; 2010 Jun;6(6):1003-14
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma and the carcinogenic role of aberrant Hedgehog signaling.
  • Basal cell carcinoma (BCC) is the most frequent cancer in the white population and its incidence appears to be increasing worldwide.
  • While the majority of BCCs arise sporadically, many cases are attributable to basal cell nevus syndrome, or Gorlin syndrome, an autosomal dominantly inherited disorder characterized by the occurrence of multiple BCCs and by extracutaneous tumors.
  • Genetic studies on patients with basal cell nevus syndrome indicate deregulation of the Hedgehog (Hh) pathway in epidermal keratinocytes as the primary event in the pathogenesis of BCC.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Cell Transformation, Neoplastic / genetics. Hedgehog Proteins / physiology. Neoplasm Proteins / physiology. Signal Transduction / physiology. Skin Neoplasms / genetics
  • [MeSH-minor] Animals. Basal Cell Nevus Syndrome / genetics. Basal Cell Nevus Syndrome / pathology. Cilia / physiology. DNA Repair. Forkhead Transcription Factors / physiology. Hair Follicle / growth & development. Humans. Keratinocytes / metabolism. Mammals / genetics. Mice. Mice, Knockout. Mice, Transgenic. PTEN Phosphohydrolase / physiology. Receptors, Cell Surface / deficiency. Receptors, Cell Surface / genetics. Receptors, Cell Surface / physiology. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / physiology. Repressor Proteins / deficiency. Repressor Proteins / genetics. Repressor Proteins / physiology. Skin / growth & development. Wnt Proteins / physiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528237.001).
  • [ISSN] 1744-8301
  • [Journal-full-title] Future oncology (London, England)
  • [ISO-abbreviation] Future Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Forkhead Transcription Factors; 0 / Hedgehog Proteins; 0 / Neoplasm Proteins; 0 / Receptors, Cell Surface; 0 / Receptors, G-Protein-Coupled; 0 / Repressor Proteins; 0 / SMO protein, human; 0 / SUFU protein, human; 0 / Smo protein, mouse; 0 / Sufu protein, mouse; 0 / Wnt Proteins; 0 / patched receptors; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 150
  •  go-up   go-down


70. Bucher S, Guerra M, Corrias F, Ribuffo D: Basal cell carcinoma of the nose requiring amputation arising after irradiation for childhood hemangioma. Anticancer Res; 2006 Nov-Dec;26(6C):4767-70
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma of the nose requiring amputation arising after irradiation for childhood hemangioma.
  • A 49-year-old female, who had undergone irradiation at six years of age as a treatment for a cutaneous nasal hemangioma, developed later a devastating basal cell carcinoma requiring sub-amputation of the nose and subsequent reconstruction with a pre-expanded forehead flap.
  • Basal cell carcinomas are now frequently reported as late sequelae of previous low-dose irradiations after 10-20 years, and patients should be aware of this possible evolution.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Hemangioma / radiotherapy. Neoplasms, Radiation-Induced / surgery. Neoplasms, Second Primary / surgery. Nose Neoplasms / surgery

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214338.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


71. Kiyici H, Bilezikçi B, Ozen O, Demirhan B: Immunohistochemical FHIT expression still exists in early lesions of basal cell carcinoma. Pathol Res Pract; 2010 Jul 15;206(7):445-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical FHIT expression still exists in early lesions of basal cell carcinoma.
  • In this study, we evaluated the expression of Fragile Histidine Triad (FHIT) in basal cell carcinoma (BCC).
  • As a primary result, there was no significant decrease in FHIT expression in early lesions of BCC.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Carcinoma, Basal Cell / metabolism. Neoplasm Proteins / biosynthesis. Skin Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20399571.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / fragile histidine triad protein; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


72. Essers B, Nieman F, Prins M, Smeets N, Neumann H: Perceptions of facial aesthetics in surgical patients with basal cell carcinoma. J Eur Acad Dermatol Venereol; 2007 Oct;21(9):1209-14
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perceptions of facial aesthetics in surgical patients with basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC) is a non-melanoma form of skin cancer that is frequently localized within the cervicofacial area.
  • (ii) if there was a significant difference between primary and recurrent BCC patients; and (iii) between patients who had Mohs micrographic surgery (MMS) or surgical excision (SE).
  • There was no statistically significant difference on facial aesthetics between the group with a primary or recurrent BCC and patients treated with MMS or SE.
  • [MeSH-major] Carcinoma, Basal Cell / psychology. Esthetics. Face. Skin Neoplasms / psychology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17894707.001).
  • [ISSN] 0926-9959
  • [Journal-full-title] Journal of the European Academy of Dermatology and Venereology : JEADV
  • [ISO-abbreviation] J Eur Acad Dermatol Venereol
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  •  go-up   go-down


73. Gore SM, Kasper M, Williams T, Regl G, Aberger F, Cerio R, Neill GW, Philpott MP: Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation? J Pathol; 2009 Sep;219(1):61-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuronal differentiation in basal cell carcinoma: possible relationship to Hedgehog pathway activation?
  • Although deregulated Hedgehog signalling and elevated Gli transcription factor expression are known to promote the development of basal cell carcinoma (BCC), little is known about molecular mechanisms driving the development of specific growth pattern subtypes.
  • Primary human keratinocytes retrovirally expressing GLI1(-) and GLI2(-) showed elevated levels of beta-tubulin III and ARC but not Neurofilament or GAP-43, suggesting that beta-tubulin III and Arc may be early targets of aberrant Gli expression in BCC, whereas expression of Neurofilament and GAP-43 are either later, downstream targets or under control of alternative pathways.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Gene Expression Regulation, Neoplastic. Hedgehog Proteins / genetics. Neurons / pathology
  • [MeSH-minor] Analysis of Variance. Biomarkers / analysis. Case-Control Studies. Cell Differentiation. Cells, Cultured. Cytoskeletal Proteins / genetics. GAP-43 Protein / genetics. Humans. Image Interpretation, Computer-Assisted. Immunohistochemistry. Keratinocytes / metabolism. Kruppel-Like Transcription Factors / genetics. Nerve Tissue Proteins / genetics. Neurofilament Proteins / genetics. Neuronal Plasticity. Nuclear Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction / physiology. Transcription Factors / genetics. Transduction, Genetic. Tubulin / genetics. Zinc Finger Protein GLI1

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19479712.001).
  • [ISSN] 1096-9896
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Grant] Austria / Austrian Science Fund FWF / / FWF/ P 20652; United Kingdom / Medical Research Council / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Cytoskeletal Proteins; 0 / GAP-43 Protein; 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / Neurofilament Proteins; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / Tubulin; 0 / Zinc Finger Protein GLI1; 0 / activity regulated cytoskeletal-associated protein
  •  go-up   go-down


74. Litak J, Behroozan D, Binder S: Co-existing basal cell carcinoma and blue nevus in an African-American woman. J Cutan Pathol; 2009 Oct;36(10):1114-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Co-existing basal cell carcinoma and blue nevus in an African-American woman.
  • Histopathologic examination revealed a basal cell carcinoma juxtaposed to a blue nevus.
  • Interestingly, the most common types of cutaneous collision tumors include melanocytic nevus and basal cell carcinoma.
  • This is the first documented case of a basal cell carcinoma co-existing alone with a blue nevus.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Blue / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Nevus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 John Wiley & Sons A/S.
  • (PMID = 19602062.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


75. Allen SB, Lortscher DN, Sengelmann RD: Earlier detection of patients' second primary basal cell carcinomas: a quantitative analysis. Dermatol Surg; 2007 Jan;33(1):69-72
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Earlier detection of patients' second primary basal cell carcinomas: a quantitative analysis.
  • BACKGROUND: Basal cell carcinoma (BCC) is the most common occurring cancer in humans.
  • No studies to date have compared the size of a patient's first and second primary BCC to determine whether we are detecting and treating second primary cancers at earlier stages of development.
  • OBJECTIVE: The objective was to ascertain whether patients who have had a primary BCC are diagnosed and treated for subsequent BCC at an earlier clinical stage of development.
  • METHODS AND MATERIALS: We performed a 4-year retrospective chart review of all patients presenting for Mohs micrographic surgery for two separate primary BCC.
  • We compared the presenting clinical size of patients' first and second primary BCC.
  • RESULTS: We found a statistically significant decrease in size of the second primary BCC when compared to the first primary BCC (p<.0001).
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Neoplasms, Second Primary / pathology. Skin Neoplasms / pathology. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Early Diagnosis. Female. Follow-Up Studies. Humans. Male. Middle Aged. Mohs Surgery. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214681.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Bath-Hextall F, Leonardi-Bee J, Smith C, Meal A, Hubbard R: Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study. Int J Cancer; 2007 Nov 1;121(9):2105-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence of skin basal cell carcinoma. Additional evidence from a UK primary care database study.
  • We determined the trends in incidence of skin basal cell carcinoma (BCC) using a primary care population-based cohort study in the UK.
  • 11,113 adults with a BCC diagnosis were identified from a total of 7.22 million person-years of data between 1996 and 2003 from the Health Improvement Network database.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Databases, Factual / trends. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17640064.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


77. Carneiro BA, Watkin WG, Mehta UK, Brockstein BE: Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest; 2006 Jun-Jul;24(4):396-400
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia.
  • Basal cell carcinoma (BCC) is usually a benign and indolent cancer cured in greater than 95 percent of cases.
  • We report a case of BCC metastatic to the lungs, occurring 17 years after the primary BCC was noticed, that responded to carboplatin and paclitaxel on 3 occasions.
  • The patient also developed pure red cell aplasia (PRCA).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Basal Cell / secondary. Lung Neoplasms / secondary. Paraneoplastic Syndromes / complications. Red-Cell Aplasia, Pure / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Pure red cell aplasia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16777692.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


78. Ueno T, Futagami A, Mitsuishi T, Niimi Y, Shimoda T, Kawana S: Basal cell carcinoma arising on a chronic lymphedematous leg. J Dermatol; 2009 Dec;36(12):646-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma arising on a chronic lymphedematous leg.
  • We describe a case of an 82-year-old Japanese woman with basal cell carcinoma (BCC) on the leg with secondary chronic lymphedema due to treatment for uterine cancer.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Lymphedema / complications. Skin Neoplasms / complications
  • [MeSH-minor] Aged. Aged, 80 and over. Chronic Disease. Female. Humans. Leg. Neoplasms, Second Primary / complications. Neoplasms, Second Primary / pathology. Uterine Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Lymphedema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19958449.001).
  • [ISSN] 1346-8138
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Busam KJ, Halpern A, Marghoob AA: Malignant melanoma metastatic to a basal cell carcinoma simulating the pattern of a basomelanocytic tumor. Am J Surg Pathol; 2006 Jan;30(1):133-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma metastatic to a basal cell carcinoma simulating the pattern of a basomelanocytic tumor.
  • We report a case of metastatic melanoma colliding with and colonizing a basal cell carcinoma (BCC) on the head of a 69-year-old man.
  • The man had a prior history of multiple primary BCCs and melanomas.
  • One of his primary melanomas, on the left scalp, recurred locally and resulted in the development of numerous in-transit metastases.
  • The intimate association of melanoma cells within the nodules of BCC simulated the pattern of so-called "malignant basomelanocytic tumor," a recently proposed novel entity.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Neoplasm Recurrence, Local / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16330954.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Williams JV, Revington PJ: Facial basal cell carcinoma in a young patient with Crohn disease. J Craniofac Surg; 2010 Nov;21(6):1996-8
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Facial basal cell carcinoma in a young patient with Crohn disease.
  • A 26-year-old man with Crohn disease developed a 10-mm-diameter facial basal cell carcinoma.
  • The wound was closed by primary closure, and he made an uneventful postoperative recovery with a satisfactory cosmetic result.
  • There are few articles in the literature on this topic, and the authors believe this to be the first documented case of facial basal cell carcinoma occurring in the context of Crohn disease.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Crohn Disease / complications. Facial Neoplasms / diagnosis. Nose Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119483.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 9PHQ9Y1OLM / Prednisolone; MRK240IY2L / Azathioprine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


81. Ball EA, Hussain M, Moss AL: Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review. Clin Exp Dermatol; 2005 May;30(3):259-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Squamous cell carcinoma and basal cell carcinoma arising in a naevus sebaceous of Jadassohn: case report and literature review.
  • The development of a basal cell carcinoma within a naevus sebaceous of Jadassohn (NSJ) has commonly been reported.
  • However, the development of a squamous cell carcinoma (SCC) is rare.
  • Of these only one was a case of simultaneous occurrence of squamous and basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / etiology. Carcinoma, Squamous Cell / etiology. Neoplasms, Multiple Primary / etiology. Nevus / complications. Sebaceous Gland Neoplasms / complications

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15807685.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  •  go-up   go-down


82. Hafner C, Klein A, Landthaler M, Vogt T: Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis. Dermatology; 2009;218(3):278-81
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality of basal cell carcinoma arising in an epidermal nevus. New insights provided by molecular analysis.
  • We report a case of a patient who developed 2 basal cell carcinomas in an extensive epidermal nevus on the trunk.
  • Molecular analysis of a biopsy containing both basal cell carcinoma and epidermal nevus revealed a PIK3CA mutation.
  • Further analysis suggested that this mutation is present in the basal cell carcinoma rather than in the epidermal nevus.
  • The results favour an independent origin of the basal cell carcinoma, although a possible clonal relationship between both lesions cannot be completely excluded on the basis of the molecular genetic findings.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Neoplasms, Multiple Primary / genetics. Nevus / genetics. Skin Neoplasms / genetics

  • Genetic Alliance. consumer health - Nevus.
  • Genetic Alliance. consumer health - Epidermal nevus.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • MedlinePlus Health Information. consumer health - Moles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2008 S. Karger AG, Basel
  • (PMID = 19122450.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.1.137 / PIK3CA protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 3
  •  go-up   go-down


83. Brellier F, Bergoglio V, Valin A, Barnay S, Chevallier-Lagente O, Vielh P, Spatz A, Gorry P, Avril MF, Magnaldo T: Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures. Oncogene; 2008 Nov 20;27(51):6601-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygous mutations in the tumor suppressor gene PATCHED provoke basal cell carcinoma-like features in human organotypic skin cultures.
  • Basal cell carcinoma of the skin is the most common type of cancer in humans.
  • In this study, we took advantage of the natural genotype (PATCHED(+/-)) of healthy keratinocytes expanded from patients with the nevoid basal cell carcinoma or Gorlin syndrome to mimic heterozygous somatic mutations thought to occur in the PATCHED gene early upon basal cell carcinoma development in the general population.
  • Deciphering the phenotype of PATCHED(+/-) keratinocytes revealed slight increases of the transcriptional activators GLI1 and GLI2-the latter known to provoke basal cell carcinoma-like tumors when overexpressed in transgenic mice.
  • PATCHED(+/-) keratinocytes also showed a substantial increase of the cell cycle regulator cyclin D1.
  • These data show for the first time the physiological impact of constitutive heterozygous PATCHED mutations in primary human keratinocytes and strongly argue for a yet elusive mechanism of haploinsufficiency leading to cancer proneness.
  • [MeSH-major] Carcinoma, Basal Cell / genetics. Mutation. Receptors, Cell Surface / genetics. Skin / pathology. Skin Neoplasms / genetics
  • [MeSH-minor] Base Sequence. Cell Transformation, Neoplastic / genetics. Cells, Cultured. DNA Mutational Analysis. Female. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor / physiology. Genetic Predisposition to Disease. Heterozygote. Humans. Keratinocytes / metabolism. Keratinocytes / pathology. Male. Middle Aged. Models, Biological. Organ Culture Techniques


84. Su SY, Giorlando F, Ek EW, Dieu T: Incomplete excision of basal cell carcinoma: a prospective trial. Plast Reconstr Surg; 2007 Oct;120(5):1240-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incomplete excision of basal cell carcinoma: a prospective trial.
  • Reported rates of incomplete excision of basal cell carcinoma vary widely (5 to 25 percent) among centers worldwide.
  • METHODS: From January of 2001 to December of 2002, 1214 basal cell carcinomas were excised at Peter MacCallum Cancer Centre.
  • RESULTS: The overall percentage of incomplete excision was 11.2 percent for primary excisions.
  • Risk factors for incomplete excision are the head site; morpheic, superficial, and infiltrative subtypes; lesions larger than 20 mm in diameter; the presence of multiple lesions; repair by skin graft; and recurrent and previously incompletely excised basal cell carcinomas.
  • CONCLUSIONS: This is the largest prospective study of incomplete excision of basal cell carcinomas.
  • Preoperative "red-flagging" of basal cell carcinomas most at risk of incomplete excision may lead to a better result.
  • [MeSH-major] Carcinoma, Basal Cell / ultrasonography. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Neoplasm Recurrence, Local / surgery. Prospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898596.001).
  • [ISSN] 1529-4242
  • [Journal-full-title] Plastic and reconstructive surgery
  • [ISO-abbreviation] Plast. Reconstr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Bøgelund FS, Philipsen PA, Gniadecki R: Factors affecting the recurrence rate of basal cell carcinoma. Acta Derm Venereol; 2007;87(4):330-4
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors affecting the recurrence rate of basal cell carcinoma.
  • The aim of this retrospective survey was to determine recurrence rates after treatment of basal cell carcinomas in a single academic dermatology department.
  • A total of 1016 patients with 1593 histologically verified basal cell carcinomas (n=1212 primary and n=381 relapsing) were included.
  • The relapse rate for primary basal cell carcinomas on the scalp was highest (odds ratio (OR)=2.8, 95% confidence interval (CI) 1.5-5.3).
  • T2 and T3 tumours showed a 2- and 3-fold increased relapse rate, respectively, compared with T1 basal cell carcinomas.
  • Recurrent basal cell carcinomas had a higher relapse rate than primary lesions (OR=1.8, CI=1.4-2.2).
  • Thus, in an uncontrolled, real-life situation curettage or photodynamic therapy are associated with significantly higher relapse risk than excision and radiotherapy and therefore should not be used for high risk primary tumours or recurrent tumours.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Neoplasm Recurrence, Local / epidemiology. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17598036.001).
  • [ISSN] 0001-5555
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Sweden
  •  go-up   go-down


86. Eisner JM, Russell M: Cartilage hair hypoplasia and multiple basal cell carcinomas. J Am Acad Dermatol; 2006 Feb;54(2 Suppl):S8-10
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cartilage hair hypoplasia and multiple basal cell carcinomas.
  • An increased incidence of malignancy has been reported in this condition, but basal cell carcinoma and CHH has not previously been reported in the dermatology literature.
  • We report the case of a 25-year-old woman with CHH and multiple basal cell carcinomas.
  • A causal relationship is conceivable and, therefore, for patients with CHH, dermatologists should be aware of a possible increased risk of basal cell carcinomas.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Hair / pathology. Immunologic Deficiency Syndromes / complications. Osteochondrodysplasias / complications. Skin Neoplasms / complications
  • [MeSH-minor] Adult. Female. Humans. Neoplasms, Multiple Primary / complications

  • Genetic Alliance. consumer health - Cartilage-Hair Hypoplasia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16428006.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Farrell T, Chang YL: Basal cell adenocarcinoma of minor salivary glands. Arch Pathol Lab Med; 2007 Oct;131(10):1602-4
MedlinePlus Health Information. consumer health - Salivary Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell adenocarcinoma of minor salivary glands.
  • Basal cell adenocarcinoma of minor salivary glands is a relatively rare slow-growing tumor with an infiltrating growth pattern.
  • The infiltrating growth pattern and likelihood of vascular and perineural involvement distinguishes basal cell adenocarcinoma from basal cell adenoma.
  • Other diagnostic considerations include adenoid cystic carcinoma and basaloid squamous carcinoma.
  • Basal cell adenocarcinomas show strong immunoreactivity to cytokeratin 7 and variable myoepithelial staining with S100.
  • It is necessary to differentiate basal cell adenocarcinoma from other basaloid cell tumors of the minor salivary glands because of the prognosis and potential differences in treatment, particularly adenoid cystic adenocarcinoma and basaloid squamous carcinoma.
  • Surgical excision with a wide margin to ensure complete removal has been suggested as the primary treatment for basal cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Salivary Gland Neoplasms / diagnosis. Salivary Glands, Minor / pathology
  • [MeSH-minor] Adenoma / diagnosis. Carcinoma, Adenoid Cystic / diagnosis. Carcinoma, Squamous Cell / diagnosis. Combined Modality Therapy. Diagnosis, Differential. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17922602.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Apaydin R, Gürbüz Y, Bayramgürler D, Bilen N: Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study. Amyloid; 2005 Mar;12(1):41-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokeratin contents of basal cell carcinoma, epidermis overlying tumour, and associated stromal amyloidosis: an immunohistochemical study.
  • We investigated the expression of CKs immunohistochemically in basal cell carcinomas (BCCs), epidermis overlying tumour, and skin tumor-associated amyloidosis (STA).
  • The primary antibodies of CK1-8 (AE3), CK10 (DEK-10), CK14 (LL002), CK17 (E3), CK18 (DC10), CK19 (KS19.1), CK 5/6/18 (LP34), CK8/18 (5D3) were applied to the section immunohistochemically.
  • [MeSH-major] Amyloidosis / metabolism. Carcinoma, Basal Cell / metabolism. Epidermis / metabolism. Keratins / metabolism. Skin Neoplasms / metabolism. Stromal Cells / metabolism

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16076610.001).
  • [ISSN] 1350-6129
  • [Journal-full-title] Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis
  • [ISO-abbreviation] Amyloid
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


89. Smucker PS, Smith JL: Multifocal desmoplastic medulloblastoma in an african-american child with nevoid basal cell carcinoma (gorlin) syndrome. Case report. J Neurosurg; 2006 Oct;105(4 Suppl):315-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multifocal desmoplastic medulloblastoma in an african-american child with nevoid basal cell carcinoma (gorlin) syndrome. Case report.
  • The authors present the case of a 2.5-year-old African-American boy with desmoplastic medulloblastoma (MB) and nevoid basal cell carcinoma syndrome (NBCCS), also known as Gorlin syndrome, an autosomal dominant disorder resulting from mutations in the patched (PTCH) gene that predisposes to neoplasias (including basal cell carcinomas [BCCs] and MB) and to widespread congenital malformations.
  • The diagnosis of NBCCS was suspected based on the clinical examination, patient and family medical histories, and histopathological characteristics of the tumor.
  • The diagnosis of NBCCS was confirmed by DNA testing, which revealed a novel mutation in the PTCH gene.
  • Although only a small number of patients with MB have NBCCS, the diagnosis must be considered because radiotherapy in such patients can lead to the formation of BCCs and other intracranial neoplasms within the irradiated field.
  • This case emphasizes the importance of obtaining thorough family and patient medical histories and of carefully examining the patient and close relatives for signs of NBCCS to avoid the potentially devastating consequences of missing this diagnosis.
  • [MeSH-major] African Americans. Basal Cell Nevus Syndrome / diagnosis. Brain Neoplasms / diagnosis. Cerebellar Neoplasms / diagnosis. Cerebral Ventricle Neoplasms / diagnosis. Medulloblastoma / diagnosis. Neoplasms, Multiple Primary / diagnosis
  • [MeSH-minor] Child, Preschool. Cranial Fossa, Posterior. Humans. Magnetic Resonance Imaging. Male. Mutation. Receptors, Cell Surface / genetics


90. Sherry KR, Reid LA, Wilmshurst AD: A five year review of basal cell carcinoma excisions. J Plast Reconstr Aesthet Surg; 2010 Sep;63(9):1485-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A five year review of basal cell carcinoma excisions.
  • In the Tayside plastic surgical unit where this study was carried out, regular audits of all excised basal cell carcinomas have taken place routinely every three months for over ten years.
  • A five-year review of excised basal cell carcinomas was undertaken between 1st February 1999 and 31st January 2004.
  • A total of 3006 primary lesions were excised and the incomplete excision rate was 3.2%.
  • Further treatment and follow-up of patients after surgically excised basal cell carcinoma is discussed.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Great Britain / epidemiology. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm, Residual. Reoperation. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 19837017.001).
  • [ISSN] 1878-0539
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


91. Kaplan AL, Weitzul SB, Taylor RS: Longitudinal diminution of tumor size for basal cell carcinoma suggests shifting referral patterns for Mohs surgery. Dermatol Surg; 2008 Jan;34(1):15-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Longitudinal diminution of tumor size for basal cell carcinoma suggests shifting referral patterns for Mohs surgery.
  • OBJECTIVE: The objective was to examine whether referral patterns for basal cell carcinoma (BCC) at an academic Mohs surgery practice have shifted over recent years toward referral for smaller, lower risk tumors.
  • Statistical analyses were used to identify differences in tumor size, distribution by anatomic site, and primary versus recurrent status.
  • CONCLUSIONS: Findings at our institution suggest that in recent years, referral patterns have shifted toward a preference for Mohs surgery for the treatment of smaller, primary BCCs.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Mohs Surgery. Referral and Consultation / trends. Skin Neoplasms / pathology
  • [MeSH-minor] Humans. Longitudinal Studies. Neoplasm Staging. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18053056.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Mc Menamin ME, Goh SG, Poblet E, Gostelow BE, Robson A, Calonje E: Sarcomatoid basal cell carcinoma--predilection for osteosarcomatous differentiation: a series of 11 cases. Am J Surg Pathol; 2006 Oct;30(10):1299-308
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid basal cell carcinoma--predilection for osteosarcomatous differentiation: a series of 11 cases.
  • Primary cutaneous carcinomas rarely show heterologous malignant mesenchymal differentiation.
  • We report 11 cases of sarcomatoid basal cell carcinoma (BCC) with osteosarcomatous differentiation.
  • One case showed a purely osteoclastic giant cell rich malignant mesenchyme, interpreted as representing early stages of osteosarcomatous transformation.
  • Previously unreported in sarcomatoid BCC, the mesenchymal component of another two cases displayed predominant malignant giant cell tumor like areas and 1 further case disclosed areas reminiscent of telangiectatic osteosarcoma.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinosarcoma / pathology. Cell Transformation, Neoplastic / pathology. Osteosarcoma / pathology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001162.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


93. Cheretis C, Angelidou E, Dietrich F, Politi E, Kiaris H, Koutselini H: Prognostic value of computer-assisted morphological and morphometrical analysis for detecting the recurrence tendency of basal cell carcinoma. Med Sci Monit; 2008 May;14(5):MT13-19
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of computer-assisted morphological and morphometrical analysis for detecting the recurrence tendency of basal cell carcinoma.
  • BACKGROUND: Nuclear morphometry may provide useful diagnostic and prognostic information about basal cell carcinomas (BCCs) of the skin.
  • MATERIAL/METHODS: A morphometric analysis was performed on histological sections of 52 primary BCCs which recurred and of 52 cases of BCC which did not recur.
  • RESULTS: Increased patient age, multiple localization of BCCs at the time of diagnosis, and a low degree of peripheral palisading at the histological sections of BCCs were associated with BCC recurrence and consequently worse disease-free survival (DFS).
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Diagnosis, Computer-Assisted / methods. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Algorithms. Cell Nucleus / metabolism. Female. Humans. Image Processing, Computer-Assisted. Male. Models, Statistical. Prognosis. Recurrence. Software. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443558.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  •  go-up   go-down


94. Love WE, Bernhard JD, Bordeaux JS: Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol; 2009 Dec;145(12):1431-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review.
  • OBJECTIVES: To conduct a systematic review to determine clearance rates and adverse effects of topical imiquimod or fluorouracil therapy in the treatment of nonmelanoma skin cancers such as basal (BCC) and squamous cell carcinoma (SCC), and to develop recommendations for the use of topical imiquimod or fluorouracil to treat BCC and SCC.
  • Based on the available evidence, the strength of any recommendations for the use of these 2 agents in the primary treatment of these tumors is weak.
  • [MeSH-major] Aminoquinolines / pharmacokinetics. Antineoplastic Agents / pharmacokinetics. Carcinoma, Basal Cell / drug therapy. Carcinoma, Squamous Cell / drug therapy. Fluorouracil / pharmacokinetics. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20026854.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 47
  •  go-up   go-down


95. Shieh JJ, Liu KT, Huang SW, Chen YJ, Hsieh TY: Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. J Invest Dermatol; 2009 Oct;129(10):2497-506
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells.
  • Myeloid cell leukemia-1 (Mcl-1, Mcl-1L) is an anti-apoptotic protein of the Bcl-2 family that acts as a critical molecule in apoptosis control.
  • In this study, we found an imbalance between the expression levels of Mcl-1L and Mcl-1S in the skin basal cell carcinoma (BCC) cell line when compared with primary keratinocytes.
  • This shift increases the level of pro-apoptotic Mcl-1S and reduces the level of anti-apoptotic Mcl-1L, which induces apoptosis in BCC cells and AGS cells, a human gastric adenocarcinoma epithelial cell line.
  • [MeSH-major] Alternative Splicing / drug effects. Apoptosis / drug effects. Carcinoma, Basal Cell / pathology. Oligonucleotides, Antisense / pharmacology. Proto-Oncogene Proteins c-bcl-2 / genetics. RNA, Messenger / genetics. Skin Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Cell Line, Tumor. Humans. Keratinocytes / metabolism. Keratinocytes / pathology. Myeloid Cell Leukemia Sequence 1 Protein. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19369967.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / Oligonucleotides, Antisense; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger
  •  go-up   go-down


96. Unlü RE, Altun S, Kerem M, Koç MN: Is it really necessary to make wide excisions for basal cell carcinoma treatment? J Craniofac Surg; 2009 Nov;20(6):1989-91
MedlinePlus Health Information. consumer health - Surgery.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is it really necessary to make wide excisions for basal cell carcinoma treatment?
  • Basal cell carcinoma (BCC) is the common malignancy at the skin arising from the cells of the basal layer of the epithelium or from the external root sheath of the hair follicle.
  • In our study, we make a treatment plan of excising the primary BCC with its natural tumor margin.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Skin Neoplasms / surgery. Surgical Procedures, Operative / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / prevention & control. Neoplasm, Residual / prevention & control

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19881375.001).
  • [ISSN] 1536-3732
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Kaur P, Mulvaney M, Carlson JA: Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis. Am J Dermatopathol; 2006 Aug;28(4):293-307

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma progression correlates with host immune response and stromal alterations: a histologic analysis.
  • Basal cell carcinoma (BCC) can be subclassified into low- and high-risk types for local recurrence.
  • To determine whether these types of BCC correlate with alterations in local host immune response and stroma and whether these changes follow stepwise histologic progression from low- to high-risk subtypes, we assessed the clinicopathologic features in 175 consecutive primary (nonrecurrent) BCC excision specimens.
  • [MeSH-major] Carcinoma, Basal Cell / immunology. Carcinoma, Basal Cell / pathology. Stromal Cells / immunology. Stromal Cells / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Shape. Disease Progression. Female. Humans. Inflammation / immunology. Inflammation / pathology. Male. Middle Aged. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16871032.001).
  • [ISSN] 0193-1091
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Muchemwa FC, Nakatsura T, Ihn H, Kageshita T: Heat shock protein 105 is overexpressed in squamous cell carcinoma and extramammary Paget disease but not in basal cell carcinoma. Br J Dermatol; 2006 Sep;155(3):582-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heat shock protein 105 is overexpressed in squamous cell carcinoma and extramammary Paget disease but not in basal cell carcinoma.
  • OBJECTIVES: To assess the expression of HSP105 in skin cancers including extramammary Paget disease (EMPD), cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).
  • Immunohistochemistry results showed that 56% of EMPD, 60% of primary and 100% of metastatic SCC highly expressed HSP105 while only 13% of BCC lesions showed increased staining.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. HSP110 Heat-Shock Proteins / metabolism. Neoplasm Proteins / metabolism. Paget Disease, Extramammary / metabolism. Skin Neoplasms / metabolism


99. Richmond-Sinclair NM, Pandeya N, Ware RS, Neale RE, Williams GM, van der Pols JC, Green AC: Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population. J Invest Dermatol; 2009 Feb;129(2):323-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence of basal cell carcinoma multiplicity and detailed anatomic distribution: longitudinal study of an Australian population.
  • A proportion of individuals are affected multiple times by basal cell carcinoma (BCC), but the rate and extent to which this occurs is unknown.
  • We therefore prospectively estimated BCC incidence in a subtropical Australian population, focusing on the rate at which persons develop multiple primary BCCs and the precise anatomic sites of BCC occurrence.
  • The incidence of persons affected multiple times by primary BCC was 705 per 100,000 person years compared to an incidence rate of people singly affected of 935 per 100,000 person years.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Carcinoma, Basal Cell / pathology. Face / pathology. Skin Neoplasms / epidemiology. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18668137.001).
  • [ISSN] 1523-1747
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


100. Janisson-Dargaud D, Durlach A, Lorenzato M, Grange F, Bernard P, Birembaut P: Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma. J Cutan Pathol; 2008 Oct;35(10):916-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aneuploidy, but not Ki-67 or EGFR expression, is associated with recurrences in basal cell carcinoma.
  • BACKGROUND: Basal cell carcinoma (BCC), the most common skin cancer, has an overall excellent prognosis, but recurrences are frequent.
  • METHODS: In order to evaluate the prognostic value of Epidermal Growth Factor Receptor (EGFR) expression, Ki-67 antigen expression and DNA ploidy, we compared primary tumors in 20 patients who had subsequent local recurrences and 20 matched controls without recurrences.
  • In contrast, we found that 78% of primary BCC in patients who experienced recurrences vs. 32% in the control group were aneuploid (p = 0.005).
  • [MeSH-major] Aneuploidy. Carcinoma, Basal Cell / genetics. Ki-67 Antigen / biosynthesis. Neoplasm Recurrence, Local / genetics. Receptor, Epidermal Growth Factor / biosynthesis. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Cutan Pathol. 2009 Jun;36(6):713-4 [19515054.001]
  • (PMID = 18537864.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down






Advertisement